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ABSTRACT
Metal ions play a major role in a wide range of biological processes in the human body. 
Metal ions in low-molecular weight complexes are of particular interest because of their 
greater 'mobility' and 'reactivity' compared to the high-molecular weight protein-bound 
metal ions. In this project, low-molecular weight metal ions encountered in vivo due to 
bone and joint disease are studied, namely gold, titanium and iron metal ions.
Gold compounds such as disodium aurothiomalate (Myocrisin) have been used for over 
50 years in the treatment of rheumatoid arthritis (RA). As gold 0) acts like a soft Lewis 
acid, it possesses a high affinity for thiol ligands and therefore primarily distributes itself 
amongst protein and to some extent non-protein thiol groups in vivo. Most of the gold is 
bound to the protein serum albumin, principally at the sulphydryl site Cys(34)-SH, and a 
smaller amount is bound to immunoglobulins. A small amount of the total circulating 
gold is present as low-molecular weight or "free" gold, which is likely to play an 
important role in gold transportation processes and the attainment of chemical equilibrium 
of gold between the protein binding sites.
In this study the concentration of low-molecular weight gold in the biological fluids of 
RA patients undergoing gold drug therapy (chrysotherapy) was analysed. The biological 
samples were centrifuged in order to obtain ultrafiltrate which would be free of high- 
molecular weight gold. The ultrafiltrate, containing the low-molecular gold was treated 
with potassium cyanide to facilitate the production of an auro(I)cyanide complex which 
could detected and quantified by the use of high pressure liquid chromatography (HPLC) 
in conjunction with ultra-violet (UV) detection at a wavelength of 211 nm. HPLC 
provided a method that was sensitive to the low concentrations found. The results 
obtained were backed up by measuring the "free" gold concentration by means of 
flameless atomic absorption spectrometry (AAS).
In addition the chemical nature of titanium ions found in localised darkly stained tissue 
adjacent to titanium-aluminium-vanadium hip implants was investigated. The production 
of the dark blue/black complex seen in the affected tissue was simulated in vitro by 
synthetic pathways. The spéciation of the titanium (III)/titanium (IV) complexes in the 
biological matrices was investigated with Fourier transform infra red (FTIR) spectroscopy
and high field proton nuclear magnetic resonance (NMR) with a Hahn spin echo pulse 
sequence.
The chemical nature of non-protein bound iron present in knee joint synovial fluid 
obtained from RA patients was also investigated by use of NMR.
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1. INTRODUCTION
1.1 METAL IONS IN BIOLOGICAL SYSTEMS
Metal ions play an important role in a wide range of biological processes. The 
function of the ion varies considerably depending on the process involved. There 
are four major ways in which the metal ions can act in the body:
a) in trigger and control mechanisms,
b) in a structural context,
c) as Lewis acids,
d) as Redox catalysts^.
a) Trigger and Control Mechanisms - The cations sodium (Na+), potassium (K+), 
magnesium (Mg2+), and calcium (Ca2+) are responsible for a number of trigger 
and control mechanisms, acting as charge carriers. Sodium and potassium ions act 
to provide osmotic balance and electrolyte current. Sodium ions are found outside 
the cell and potassium ions within the cell. The sodium-potassium concentration 
gradient across the cell membrane is important physiologically. The difference in 
the concentration results in the generation of potential difference between the two 
sides of the membrane. A nerve impulse is conducted along the membrane when 
there is a rapid influx of sodium ions into the nerve cells resulting from a 
temporary reversal of the membrane's selectivity towards sodium and potassium 
ions. An example of the trigger mechanism is provided by the sudden influx of 
calcium ions into muscle cells. Normally calcium is excluded from the cells and 
magnesium ions are present, but the influx of calcium ions results in the activation 
of certain enzymes and hence muscle contraction.
b) Structural Influmces - Metal ions stabilise certain protein configurations so 
affecting the physical and biological properties of the protein. Calcium, 
magnesium and manganese can influence the equilibrium between the native and 
reversibly denatured protein. Metal ions such as nickel (II) act as templates, 
bringing reacting groups into a correct orientation for reaction. The presence of 
metal ions is also important in the maintaining of the structure of the cell walls. 
Calcium and magnesium are both present in the body at a greater concentration 
than expected if their roles were purely those of enzyme activators. It is probable 
that these divalent ions participate in a stiffening mechanism for the lipoprotein 
membranes by bridging neighbouring carboxylate groups.
c) Lewis acid behaviour - Metal ions in biological systems can accept electron 
pairs and so act as Lewis acids catalysing certain enzyme reactions. Calcium, 
manganese and particularly magnesium act by activating enzymes associated with 
the phosphate system. Magnesium is required in all stages of vitamin B, 
biosynthesis. Zinc is associated with hydrolytic enzymes.
d) Redox behaviour - In redox reactions the metal ions catalyse valance changes in 
the substrates. Specificity of the enzyme for the metal tends to be much higher. 
The transition metal ions are involved in a wide range of catalytic functions, 
whilst zinc also acts as a catalyst of hydride transfer. Ten trace metals are 
essential to warm blooded animals, these are copper, iron, zinc, cobalt, 
molybdenum, chromium, tin, vanadium and nickel. The more important metals in 
biological redox processes are iron, copper and cobalt with molybdenum involved 
to a lesser extent. The processes range from electron transfer, oxygen atom and 
hydroxyl group incorporation to hydrogen atom and hydride removal. Iron is 
involved in the respiratory process, binding oxygen when incorporated in 
haemoglobin and myoglobin. It is also a component of various cytochromes.
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peroxidases and catalases. In the body there is an iron transport system controlled 
by the iron enzymes ferritin and transferrin. Copper is present in about 12 
enzymes whose functions range from the utilisation of iron to the pigmentation of 
the skin. Two copper containing enzymes of importance are amine oxidase which 
is necessary for the formation of elastin and bone collagen, and tyrosinase utilised 
in the formation of melanin. Copper is also required for the release of iron from 
its storage protein ferritin.
As well as native metal ions in vivoy there can be present those such as gold, 
titanium, mercury, etc., which do not occur naturally but are introduced 
deliberately for therapeutic reasons or accidentally with deleterious effect.
1.2 METAL IONS IN BONE AND JOINT DISEASE
The metal ions encountered in bone and joint disease can be found naturally in 
vivo like copper and iron or can be present due to introduction into the body for 
medical reasons. In this study gold, titanium and iron metal ions encountered in 
vivo due to bone and joint disease are of interest. Gold and titanium are introduced 
into the biological system of diseased patients for medicinal purposes.
Gold-containing drugs have been used therapeutically to treat rheumatoid arthritis 
for 55 years^. Whilst not curing the disease, they can produce remission. The trea­
tment usually involves weekly injections of gold drugs, followed by maintenance 
therapy at less regular intervals. The majority of gold drugs administered contain 
sulphur bound gold. Although there is no single mechanism to completely explain 
the action of antiarthritic drugs in this as yet not fully understood inflammatory 
disease, their action is thought to involve the blocking of reactive thiol sites on the 
membrane proteins such as albumin and immunoglobulin G^.^. The gold
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administered is widely distributed in the plasma and serum, reflecting the lack of 
natural systems for transport and storage. The tissue distribution of gold shows 
that the greatest concentrations occur in the liver, kidney, spleen and lymph node. 
The levels of gold present in the body vary from patient to patient, however, 
unfortunately, the gold blood levels do not correlate with either clinical benefits or 
with toxicity^.
Titanium metal ions are introduced into the body by way of titanium alloy hip 
implants. The titanium implants or prostheses are used in standard hip replacement 
operations which are performed when the patient's hip joint is badly eroded or 
broken due to the thinning and increased brittleness of the bone from osteoporosis 
or erosion from rheumatoid arthritis. Titanium has been used as a surgical implant 
material because of its excellent mechanical properties, resistance to corrosion and 
biocompatability^ .^g. However recently a number of workers have reported the 
presence o f dark staining around the titanium alloy prostheses upon revision 
surgery due to loosening of the implant’ io.ii. This dark staining is found to be 
due to titanium. This suggests that titanium is not as inert as originally thought 
and that the metal interacts with the biological environment.
It is known that rheumatoid arthritis leads to altered serum levels of copper and 
iron 12. There are raised levels of copper in the serum of rheumatoid arthritis 
sufferersi3. The chief source of serum copper is ceruloplasmin, which though not 
an oxygen carrier has important oxidase activity. The increase in copper is mainly 
due to an increase in the ceruloplasmin content of the serum. The ceruloplasmin is 
a protein responsible for copper transfer to apoenzymes and also for the 
mobilisation of iron from the liver to the blood. Since the levels of copper in the 
liver actually fall in the diseased state, with a rise in the serum level, it has been 
suggested that the rise in copper levels is a physiological response to the disease.
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Iron is naturally present in human serum, however it has been previously reported 
that low molecular weight redox active iron complexes are present in the knee 
joint synovial fluid of patients with rheumatoid arthritis. These iron complexes can 
readily promote the generation of highly reactive free radical species which can 
attack a wide range of endogenous molecules to produce modified chemical 
species. These degradation products can themselves stimulate synovitis and 
progressive joint destruction.
A spéciation of these metal ions would lead to a greater understanding of their 
roles and modes of action in bone and joint disease. Due to lack of time spéciation
of copper within the rheumatoid arthritis patients was not investigated in this 
study.
1.3 RHEUMATOID ARTHRITIS
Rheumatoid arthritis is a chronic inflammatory disease that primarily affects 
peripheral joints and is characterised by inflammation of the synovium which leads 
to destructive, erosive changes in the joint. The exact causes of rheumatoid 
arthritis are not known. In general females are three times as likely to be affected 
as males. It is a common disease with overall 2% of males and 5% of females 
affected in the United Kingdom. The age of onset ranges from childhood to over 
75 years of age, however rheumatiod arthritis mainly devlops between 35 to 50 
years of age^^. The onset of the disease primarily affects the hands and feet, with 
new joint involvement developing irregularly to include the larger limb joints such 
as ankles, knees, elbows, shoulders and often later the hip joints. Movable joints 
are all synovial joints (Figure 1.1), possessing a synovial membrane which 
produces a synovial fluid to lubricate the movement of the joint. It is these joints 
that are affected by rheumatoid arthritis.
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Ligament
Articular Cartilage 
Synovial Fluid
Figure 1.1 Section Through a Synovial Joint
The disease is characterised by remissions that occur spontaneously for no known 
reasons. Very little joint pain can be experienced over many years, only to enter 
another phase with severe joint swelling and disability. Rheumatoid arthritis affects 
mainly joints and synovial tissue, subsequently destroying the tissue, cartilage or 
bone irreversiblyis. The production of synovial fluid, the natural joint lubricant, is 
increased but its viscosity is much below normal. The dectease in viscosity is due
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to the breakdown of the polysaccharide hyaluronic acid to lower molecular weight 
moieties. It has been postulated that the derogatory action of free radical reactions 
leads to the degradation of the hyaluronic acid^^.
1.3.1 Histology o f Rheumatoid Arthritis
Rheumatoid arthritis is a chronic and acute inflammation of the joints, with 
eventual proteolytic degradation of the affected tissue. Inflammation encompasses a 
dynamic mixed response of chemical, cellular and extracellular changes in the 
body due to many different inticing agentsi^-^o, 7he first sign of inflammation is 
the dilation of the arteries and veins in the affected tissue, resulting in increased 
blood circulation. The white blood corpuscles, the leucocytes, begin to adhere to 
the inner surface of the blood vessels. Gradually the leucocytes push their way 
through the walls of the smaller capillaries, migrating into the surrounding tissue 
along with fluid material from the blood and a few red blood cells, erythrocytes. 
This process is known as diapedesis and is responsible for the swelling which is a 
characteristic sign of inflammation.
The immunological events occurring in synovial tissue affected by rheumatoid 
arthritis are not completely understood and the onset of this inflammatory disease 
appears as yet to have no causative stimulus^^. Rheumatoid arthritis is thought to 
arise due to biphasic processes; the first exudation and the second granulation. The 
exudative stage involves the action of inflammatory mediators, such as kinins and 
prostglandins, which lead to an alteration of the permeability of the synovial 
membrane blood vessels. This change in vascular permeability allows various cell 
types, including phagocytic cells such as polymorphnuclear leucocytes (PMN) and 
lymphocytes, to traverse and migrate into the extracellular spaces in the synovial 
fluid. The polymorphnuclear leucocytes (PMN), including neutrophils, contain
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both proteolytic (elastase and cathepsin G) and oxidative (myeloperoxidase) 
enzymes which are normally stored in cytoplasmic granules. However on 
encountering immune complexes or antigens, rapid degranulation associated with 
phagocytosis occurs and this is known as the granulation phase. With 
phagocytosis, the proteolytic and oxidative enzymes are often released into the 
tissues themselves. Normally it is the major plasma inhibitor, alpha-1-proteinase 
inhibitor (of-l-PI) that can also penetrate vascular walls, which exerts control on 
connective tissue proteolysis2i. However, because of the massive infiltration of 
PMN leucocytes and the inactivation of the a-l-P I by the myeloperoxidase-H202- 
Cl- system22 which occurs during phagocytosis, the ability of the tissue levels of 
this inhibitor to protect the tissues from proteolysis are markedly reduced. Hence 
the uncontrolled digestion of connective tissues may occur resulting in severe 
damage associated with diseases such as rheumatoid arthritis. Free radical damage 
of the connective tissue has also been implicated more recently23-25, Thg 
myeloperoxidase enzyme is particularly deleterious since it generates the powerful 
oxidant hypochlorite ion (OCl ) from hydrogen peroxide (H2O2) and the chloride 
ion. Also the activated neutrophils produce low levels of the superoxide radical 
anion (O2 ) and hydrogen peroxide which must be released into the synovial 
fluid. These highly reactive free radicals can attack biomolecules with deleterious 
effect leading to eventual connective tissue destruction.
1.3.2 Treatment of Rheumatoid Arthritis
In view of the incomplete understanding of the causes of rheumatoid arthritis, 
there are no preventative measures that can be applied to halt the onset of the 
disease. Treatment is designed to modify the course of this inflammatory joint 
disease and to reduce its structural consequences, which lead to deformity and
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consequent disability. The drug treatments currently utilised can broadly be 
classified into four groups; analgesics, corticosteroids, immunosuppresive drugs 
and slow acting drugs such as gold compounds^^-^^
Analgesics are essential as they provide pain relief and can be used in conjunction 
with more specific treatment. They are the most widely used of the antirheumatic 
drugs and include chiefly the salicylates such as aspirin. Paracetamol may 
occasionally be preferred but is usually less effective. The analgesics provide pain 
relief at low doses and are anti-inflammatory after repeated administration of high 
doses. Their anti-inflammatory action may be due to inhibition of prostglandin and 
hence reduction of vascular permeability. They act rapidly and their clinical effects 
decline promptly after the cessation of therapy. The analgesics do not prevent the 
progression of rheumatoid arthritis nor do they induce remission.
Corticosteroids administered at low levels have anti-inflammatory effects. They 
act on the blood vessel walls leading to decreased vascular permeability. They 
block the accumulation of polymorphnuclear leucocytes and monocytes at 
inflammatory sites. At high doses the corticosteroids are immunosuppressive as 
they redistribute the lymphocytes into the bone marrow. Corticosteroid dose levels 
must be restricted to those which will produce some level of suppression without, 
even over a long period, causing the patient to develop unacceptable features of 
overdose. The beneficial effects of corticosteroids such as cortisone are only 
temporary and cease when treatment is stopped.
Immunosuppresive drugs include alkylating agents such as cyclophosphamide and 
chlorambucil. Despite differences in their site and mode of action the 
immunosuppressive drugs share many features with respect to their use in the 
treatment o f rheumatoid arthritis. They are all slow acting, with several weeks 
being taken before their clinical effects are apparent and they may induce
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remission. They have a wide range of complex immunosuppressive effects. Their 
mechanism of action is unknown but they probably interfere with lymphocyte 
populations.
Slow acting drugs include mainly the gold compounds but also D-penicillamine. 
Treatment with gold containing drugs such as disodium aurothiomalate should be 
initiated once diagnosis is firmly established and when there is evidence of 
progressive disease. These drugs have a slow onset of action (6-8 weeks) with the 
clinical benefit improving over a period of months. They induce remission and 
may slow the progression of the erosive disease. The gold compounds distribute 
themselves rapidly throughout the body with a tendancy to concentrate in the areas 
of inflammation as well as within the lysosomal membranes of phagocytic cells. 
Gold compounds are thought to act by the blocking of some reactive thiol groups 
on membranes and by interfering directly with the ability of macrophages to 
behave as effector cells. The beneficial effects of gold compounds may endure 
after the cessation of treatment.
The final treatment is surgery. During surgery a badly worn joint can be replaced 
with an artificial implant such as an titanium alloy hip prostheses. These 
operations serve to prevent later disability and are often salvage operations.
1.4 GOLD DRUGS IN RHEUMATOID ARTHRITIS
1.4.1 History o f Gold Treatment
Gold was probably one of the first metals to attract the attention of man due to it 
being one of the few metals that exists in its elemental state in nature, as well as 
to the attraction of its scarcity, lusture and its non-oxidising properties. Gold was
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chiefly used for ornamental purposes, however as early as 2500 BC the Chinese 
used gold for biological benefit. The Roman historian Pliny described the use of 
gold in ashen form as a treatment for fistulas and discharges. In the thirteenth 
century gold, dissolved in aqua regia and diluted with oil, was recommmended for 
the treatment of leprosy. However it was Robert Koch who reported the first 
experimental antibacterial activity of gold salts in 1890 and paved the way for a 
sounder basis for gold therapy. Koch described in vitro antitubercular activity of 
gold cyanide and other workers reported beneficial results with the use of 
inorganic gold compounds in the treatment of skin tuberculosis, syphilis and 
lupus26. After intensive efforts in synthesis in the 1920s several gold (I) thiols 
were prepared which were stable in solution and biologically active and were less 
toxic. The development of gold thiosulphate (Sanochrisin) as a therapeutic agent 
for tuberculosis by Mollgaard in 1924, sparked off what was later termed the 
Gold Decade** (1925-1935) as clinical gold therapy flourished^^.
Lande first introduced aurothioglucose (Solganol) for the treatment of rheumatoid 
arthritis noting a significant loss of joint pain in affected patients. This treatment 
was popularised by Forestier2« who reported the beneficial action of gold salts in 
chronic rheumatoid arthritis. He employed a range of gold thiolates including 
disodium aurothiomalate (Myocrisin) which were administered intramuscularly29. 
In 1960 controlled trials by the Empire Rheumatism Councipo were carried out 
which confirmed the efficacy of gold drugs in patients suffering from rheumatoid 
arthritis. Although some patients can safely undergo gold therapy for many years, 
about 35% can suffer toxic side effects. However medical opinion remains that 
gold drugs are as effective as any other drug used to treat difficult cases of
rheumatoid arthritis and that they are one of the few drugs that can alter the 
course of the disease^i.
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1.4.2 Chrysotherapy and Structure o f Gold (I) Thiolates
Today, gold drug treatment (chrysotherapy), is still employed as it is one of the 
few regimes that can produce remission from rheumatoid arthritis. The gold (I) 
thiolates in common use in chrysothen^)y include aurothiopropanolsulphonate 
(Allochrysine) and particularly aurothiomalate (Myocrisin) and aurothioglucose 
(Solganol) (Figure 1.2). Aurothiomalate and aurothiopropanolsulphonate are water 
soluble whilst aurothioglucose is oil soluble and is injected in to the body in the 
form of an oil suspension. In this study particular interest will be devoted to 
disodium aurothiomalate and its use in chrysotherapy.
CH,OH
A u -S -C H -C O jN a
CH,CO,Na
[ij
CH2S Au
I
CH OH
I
CHjS0 3 Na
C3)
'Myocrisin' 'Solganol' 'Allochrysine'
Aurothiomalate Aurothioglucose Aurothiopropanolsulphonate
Figure 1.2 Structure of Gold (I) Thiolates Used in Chrysotherapy
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Present conventional chrysotherapy involves giving a deep intramuscular injection 
of a solution of gold drug to the patient. An initial injection of a gold compound 
containing 10 mg of gold is given to test the patient's tolerance to the drug. The 
dose is increased stepwise in the next 2-3 weeks to 25-50 mg (based on the gold 
content of the drug) and thereafter weekly 50 mg doses are administered. The 
whole course of treatment usually involves 2 g of gold. Maintenance therapy may 
be instituted consisting of 20-50 mg every 2-4 weeks^^.
The structural nature of 1:1 gold (I) thiolate drugs has previously been poorly 
defined and it is only relatively recenüy that work has been done to investigate 
their chemistry3-^-36. The complexes have often been formulated as simple 
monomers, [Au(SR>], but it has been demonstrated that the gold (I) thiolate 
complexes exist as polymeric rings (Figure 1.3), with gold achieving a linear two- 
coordination via bridging thiolate sulphur Ugands i.e [Au(SR)]g 33. However the 
exact structural composition is dependant on pH, ionic strength and temperature3^.
‘Au
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Figure. 1.3 Polymeric Ring Structure for 1:1 Gold (1) Thiolate Complexes
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Present conventional chrysotherapy involves giving a deep intramuscular injection 
of a solution of gold drug to the patient. An initial injection of a gold compound 
containing 10 mg of gold is given to test the patient's tolerance to the drug. The 
dose is increased stepwise in the next 2-3 weeks to 25-50 mg (based on the gold 
content of the drug) and thereafter weekly 50 mg doses are administered. The 
whole course of treatment usually involves 2 g of gold. Maintenance therapy may 
be instituted consisting of 20-50 mg every 2-4 weeks32.
The structural nature of 1:1 gold (I) thiolate drugs has previously been poorly 
defined and it is only relatively recentiy that work has been done to investigate 
their chemistry3?-36. jh e  complexes have often been formulated as simple 
monomers, [Au(SR)], but it has been demonstrated that the gold (I) thiolate 
complexes exist as polymeric rings (Figure 1.3), with gold achieving a linear two- 
coordination via bridging thiolate sulphur Ugands i.e [Au(SR)]g 33. However the 
exact structural composition is dependant on pH, ionic strength and temperature37.
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1.4.3 Distribution of Gold (I) Thiolate Drugs in vivo
Gold (I) is a soft Lewis acid with a low affinity for nitrogen and oxygen donor 
ligands and a high affinity for ligands which contain a thiol moiety. It is therefore 
likely that the gold from gold (I) thiolate drugs administered during chrysotherapy 
will primarily distribute itself amongst protein and non-protein thiol groups in vivo. 
Work done on the distribution of gold (I) in vivo shows that in human plasma 
where the principal source of thiol groups is albumin (cysteine-34 residue), the 
gold is predominantly albumin bound (80-90%) with smaller amounts bound to 
immunoglobulins38.39. Although gold reacts slowly with albumin the gold-albumin 
complexes formed are very stable^o. The binding plateau for albumin is not 
reached until 5 hours whereas the binding to globulins is completed in 3 
minutes38. Approximately 5-10% of total circulating gold is non-protein bound, 
low molecular mass or 'free reactive' gold. Despite their low concentration, low 
molecular mass gold species such as monomeric (L-cysteinato)gold (I) complexes 
([Au(SCys)2]-)^  ^ are likely to play a vital part in the attainment of chemical 
equilibria and various transport processes. An important part of gold (I) chemistry 
is its ability to undergo thiolate exchange and release reactions as shown in Figure
1.4 which depicts a reaction between aurothiomalate and a non-protein bound thiol 
and the formation of a gold (I) albumin complex.
The injected gold is widely distributed in the plasma and serum, reflecting the 
lack of a natural transport and storage system. The serum half-life of 
aurothiomalate (Myocrisin) is 5.5 days. Gold may persist in the body for months 
after treatment and is mainly deposited in lysosomes which upon accumulating the 
metal become electron dense and are called aurosomes^^^
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i) l/n[AuStm]„ + RSH [RS-Au-Stm]- +  H+ 
A
RSH
[Au(SR>2]- +  tmSH
ii) AlbS-Au-Stm + RSH AlbS-Au-SR +  tmSH
Figure. 1.4 Scheme for the Release of Thiomalate (tmS) from Gold (1) in vivo by i) 
Direct Attack of a Non-Protein Bound Thiol (RSH, e.g Cysteine or Glutathione) on the 
1:1 Gold (I) Thiomalate Complex (l/n(AuStmJ„) and ii) Interaction of the Non-Protein 
Bound Thiol with Gold (I) Thiomalate Bound to the Cysteine-34 
Residue of Human Serum Albumin (AlbA-Au-Stm).
Gold is also present in the synovial fluid and research into the slow development 
of synovial aurosomes has been carried out because initial arthritic damage-is 
localised in the synovium^^. Synovial levels of gold (I) are approximately half 
those of serum^. Equilibration between the two is thought possible.
Gold is mainly excreted through urine but also through faeces. Gold excreted in 
urine is predominantly protein bound, mainly bound to serum albumin as in blood 
serum^^. The presence of proteins in the urine following gold injections are due to 
proteinuria, a common side effect o f gold.
1.4.4 Mechanism o f Actkm o f Gold Drugs
There is no unique mechanism of action for gold containing antiarthritic drugs 
reflecting the diffuse nature of the initiation of the disease. The correction of the 
imbalance in the immune system as witnessed by remission during chrysotherapy.
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implies modulation of the immune response and may be linked to the regulation of 
the thiol/disulphide (RSH/RSSR) balance in the cell. It is thought that the delayed 
favourable response following injections of gold (I) thiolate drugs results from the 
ability o f gold (I) to block some critical thiol groups, such as in immuno­
globulin Figure 1.5 depicts a possible mechanism for the alteration of the
complex thiol-disulphide equilibria in vivo by polymeric 1:1 gold (I) thiolates such 
as disodium aurothiomalate.
SH
•SH S
A — Oxidation o f sulphydiyi group (brought about by oxygen or superoxide). 
B »  Intermolecuiar sulphydryl-disulphide interchange reaction.
SH HS
-SH
Figure. 1.5 Possible Mechanism for the Regulation of the Complex Thiol- 
Disulphide Equilibria in vivo by Gold (I) Thiolate Drugs.
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There are many proposed modes of action of gold drugs which may also involve 
the blockage of sulphydryl activity. These include an induced decrease in 
immunoglobulin G and suppression of lymphocyte proliferation 17.48 Gold also 
seems to enter pre-existing lysosomes and alters their behaviour so as to prevent 
the release of enzymes which would perpetuate the inflammatory process^^-52. 
Other proposed modes of action of gold drugs include the inhibition of the 
myeloperoxidase system2i, inhibition of human neutrophil collagenase53, 
inhibition of prostaglandin biosynthesis^^ and of mast cell histamine releasees, or 
the possible stimulation by gold of the T effector as well as T suppressor cells^^.
It has been reported that there is oxidative damage to the synovial fluid and the 
lipids within an inflamed rheumatoid joint^^-«). Disodium aurothiomalate 
(myocrisin) inhibits oxy radical generation in vitro , a deleterious reaction which 
can lead to depolymerisation of hyaluronic acid, disruption of lysosomal and 
cellular membranes and degradation of DNA61.62. Gold (I) thiolate drugs in vivo 
are thought to limit the oxidative damage by controlling enzyme systems involved 
in the production of reactive oxygen species (ROS) and by protecting proteins and 
enzymes against oxidative damage63.64. One possible action o f gold (I) is that it 
protects unsaturated membrane lipids and proteins against oxidative degradation 
caused by activated phagocytes that are not properly regulated. Superoxide ion 
(O2 ')» ^ product of activated phagocytes can be oxidised to an electronically 
excited singlet oxygen capable of peroxidation of unsaturated fatty acid derivatives. 
Gold (I) has been shown to be a deactivator of singlet oxygènes.
The ability of gold (I) to transport electron-donating thiolate ligands to certain 
intra- or extracellular 'target' sites is likely to be an important mechanism in the 
metals control of oxygen radical-mediated oxidative damage. Although the thiolate
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ligands in 1:1 gold (I) thiolate may exert a therapeutic effect on the release from 
gold (I) in vivo^, it is clear that the gold metal centre is an essential pre-requisite 
for the ability of gold drugs to suppress active rheumatoid arthritis.
The mechanism of action of gold drugs may not be known with certainty but a 
reasonable postulate to their chemical activity can be put forward. Much work still 
needs to be done to define the various hypotheses of chrysotherapy efficacy and 
indeed a greater understanding of rheumatoid arthritis itself and its onset and 
progression needs to be reached.
1.5 TITANIUM IMPLANTS IN BONE AND JOINT DISEASE
1.5.1 Introduction
Titanium (Ti) has been employed successfully as an implant material in medicine 
for many years67-69. jn 1940 Bothe, Beaton and Davenport^o studied local tissue 
response to various metals including commercially pure titanium (cp Ti). They 
found that it was well tolerated, and that bone, perhaps even had a tendancy to 
grow into contact with the metal. Through the years titanium and titanium alloys 
have been used increasingly in medical devices such as heart valves, cardiac 
plates, dental implants, bone plates and artificial joints. The main reason for the 
use of titanium is its resistance to the highly corrosive fluids in which an implant 
must survive. The resistance to corrosion is due to a tenacious passive oxide layer, 
which forms a thin coating on the surface of the metal.
The surface of any biomaterial is of vital importance, because it determines the 
biocompatibility and corrosion resistance of the prosthesis. In joint prostheses, low 
friction and good wear characteristics are of importance. At room temperature.
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oxidation occurs on the titanium metal surface forming an oxide layer which is 1-5 
nm thick. The oxide forms a protective layer and prevents direct contact of the 
metal with its tissue environment. The surface of the alloy usually used for 
titanium implants, Ti-6A1-4V (6% aluminium, 4% vanadium), consists of the 
oxides of titanium (Ti02) and aluminium (AI2O3), whilst pure titanium has a Ti02 
layer only. The surface chemical composition and surface microstructure of the 
implant strongly influence the chemical reactions that will take place at the 
prostheses-tissue interface'^^
1.5.2 General Chemistry o f Titanium
Titanium is the most naturally abundant transition metal after iron and the ninth 
most common element in the earths crust (average 0.6%), present in small 
amounts in practically all silicate minerals and in almost all soils. It is found in its 
oxidic mineral form (rutile, ilemite and sphene). The metal is lustrous white, with 
a density of 4.5 g cm*3 and is malleable when not contaminated with oxygen. It is 
very reactive, being the only metal to bum in nitrogen. When it forms an oxide
layer on exposure to oxygen, it becomes resistant to most chemicals and is 
considered physiologically inert.
The problems of 'working' Utanium are caused by its hardness, brittleness and 
rather poor ductility. As titanium is becoming an increasingly important structural 
metal, these problems are being overcome by alloying it with other metals. Dilute 
mineral acids have little effect at room temperature but the metal dissolves in hot 
dilute hydrochloric acid or cold dilute hydrofluoric acid. Hot concentrated nitric
acid slowly attacks the metal with the formation o f insoluble hydrated titanium 
dioxide, Ti02.nH2 O.
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The ground state outer electronic configuration is 3d2 4s2 .The maximum 
oxidation state is +4 (titanic) and it is the commonest state found as it is the most 
stable. The + 3  (titanous) and +2 states are also formed.
1.5.2.1 The Aqueous + 4  Oxidation Stale
The + 4  titanium oxidation state gives rise to largely covalent compounds. The
titanium hexaaqua-ion {[TKHjO)«]«*) is unknown, as the high charge-to-size ratio
leads to great acidity so that only hydrolysed derivatives are obtained in aqueous 
solution‘^ *‘73.
With dUute acids, such as perchloric acid {HCIO4), the thermodynamic 
equilibrium will lie as follows:
[Ti(H20)4(0H)2]2+ +  HjO [Ti(H20)3(OH)3]+ -I- H3O+ (1.1) 
Addition of a base gives the hydrous oxide precipitate:
(Ti(HjO)3(OH)3]+ + HjO i=±rri(H20)2(OH)4] +  H3O+ (1.2)
TTie hydrous oxide is normally regarded as TiOj.nHjO as there is no evidence of 
hydroxide (Ti(OH)4) formation.
1.5.2.2 The Aqueous + 3  Oxidation Stale
In Its ground state the + 3  oxidation stale, has an outer configuration of 3d '. 
Unlike titanium aV ), the Ti OH) compounds are paramagnetic -  1.7 B.M)
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and coloured through d-d absorption even when charge-transfer absorptions are 
absent. This oxidation state is less acidic than the -1-4 state, and its compounds 
show a considerably greater degree of ionic character.
The hexaaqua-ion rTi(HjO)d3* ¡s readily prepared by either reducing solutions
containing titanium a v )  with zinc and hydrochloric acid, or by electrolysis. There
IS however some substitution of the water molecules by chloride ions in high acid
concentrations, species such as [Ti(HjO)5C lp+ and [Ti(H20)4C y +  being
predominant in these solutions. Solutions containing Ti (III) are readily obtained
by dissolving the metal in hydrochloric acid. The violet aqua-ion is strongly 
acidic:-
[Ti(H20)d3+ +  H j0 ^ (T i(0 H )(H 2 0 )5 ]3 +  + H3O+ (pK, =  1.4) (1.3)
The addition of salts of weak acids to titanium aU ) solutions thus results in the 
precipiution o f the hydrous oxide. The reaction with sodium hydroxide or for 
example carbonate solution results in the evolution of carbon dioxide.
rri(H20)d3+ -t- 3H20^=ÌTi(0H)3(H20)3 +  3H3O+ (1.4)
2H3O+ + CO3 3- CO, + 3 H ,0 (1.5)
Water soluble titanium (in) salts are therefore limited to salts of strong
nonoxidising acids, that is halides and sulphates. The dark purple hydrous oxide is
often written as Ti(OH)3 but since there is considerable evidence for
•polymerisation”, in the formation of this product, it is best considered as 
T*203(«q)-
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In acidic solution Ti '^*' is a strong reducing agent (slightly stronger than the tin 
ion, Sn2+).
TÍ02+ +  2H+ +  e- ■> TP+ + H2O (E =  O.IV) (1.6)
The solution is oxidised by air and must be kept under nitrogen.
1.5.3. Titanium Alloys
At room temperature titanium forms a hexagonal close packed structure (a-Ti) 
which at 882®C is transformed into a body-centered cubic structure (B-Ti) which 
in turn melts at 1,678®C.
The addition of an alloying element, either stabilises the hexagonal a-Ti form or 
promotes the existence of the cubic fl-Ti structure. When titanium is alloyed with 
oxygen or aluminium, it gives rise to a material of the cubic 6-Ti structure which 
has improved mechanical properties. The tensile strength is increased by 35-70% 
for an additional 1% of alloying element. However if the aluminium content is 
over 9% by weight, the alloy becomes brittle due to the precipitation of TÍ3AI. 
Brittle fracture may also occur as a consequence of titanium hydride (TÍH2) 
formation. Alpha-beta alloys have a hexagonal o-Ti structure and a cubic 6-Ti 
structure, so alievating the TÍ3AI formation problem. The a-fi-alloy, TÍ-6A1-4V 
(6% aluminium, 4% vanadium) accounts for over 50% of world titanium 
production and is the chief alloy used for the manufacture of joint prostheses. It 
gives a high tensile strength (1000 MPa) with improved formability^^.
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1.5.4. The Tissue Enviioninent
The tissue environment together with blood and intestinal liquor are aqueous 
electrolytic media (approx. 1 % sodium chloride solution) at a constant temperature 
(37°C) o f about neutral or slightly acidic pH and a moderate redox potential that 
varies with pH and oxygen tension. Organic species present may act as strong
complexing agents. Implant materials are found among the transition metals and 
fall into 3 categories;
i) the noble metals, e.g. gold, platinum etc. which are immune to oxidation in the 
tissue environment
ii) metals in group 4A and 5A e.g. titanium, vanadium and zirconium which 
readily form impenetrable surface oxides.
iii) the 6A-8 groups e.g. iron.
The ii) category provides the best implants.
1.5.5. Use o f Titanium Implants
Implants serve a mechanical function, and will therefore be subjected to stress
over a long period of time whilst functioning as an integrated part of the skeleton
dunng a patients lifetime. The prosthesis, or implant must be biocompatible, that
IS It must not attack or itself be attacked by the hosting tissue. Titanium has
continually been found to be biocompatible, and commercially pure titanium (c.p
Ti) and alumina ceramics have been proposed as reference standards for 
biocompatible materials'^^.
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Animal experiments have shown that titanium implants can be hosted by the 
organism for up to 10 years without any detectable or systematic reactions'^^. 
Albrektsson et aP^ reported that implanted commercially pure titanium, after up to 
90 months within the organism was characterised by normal lamellar bone in 
direct contact with the metal. An interface zone of 20-50 nm between the implant 
and bone collagen filaments has been reported^». This type of bone-implant 
interface seems to be particular to titanium.
Unalloyed titanium is used for the prosthesis where biocompatibility of the 
implant is the highest priority. However by far the most commonly used titanium 
implant material is achieved by alloying titanium to 6% aluminium and 4 % 
vanadium. This leads to an improvement of the implant's mechanical and wear 
properties without seriously jeopardizing its biocompatibility. The fatigue strength 
of the Ti-6A1-4V alloy is 49% greater than that of commercially pure titanium and 
has approximately half the elasticity modulus (E modulus) of stainless steel or a 
Co-Cr-Mo alloy. This low modulus may be advantageous in reducing the stress 
shielding of the femur and reducing strain at the bone implant interface. The oxide 
layer, approximately 10 nm thick, that forms on the implant surface represents the 
ultimate goal for prostheses as it marries the inertness of ceramics with the 
strength of a metal. Titanium is therefore expected to resist physiologic chloride 
solutions at body temperature indefinitely.
However in recent years the presence of dark staining of the tissue adjacent to 
titanium prostheses has been noted during some revision surgery. This may point 
to the fact that titanium implants are not as biocompatible and inert within the 
biological environment as originally thought.
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1.6 IRON IN THE RHEUMATOID JOINT
As already mentioned there is little doubt that free radical reactions take place in 
the rheumatoid joint, leading to the degradation of the synovial fluid and the 
breakdown of hyaluronic acid. The formation of free radicals, such as the highly 
reactive hydroxyl radical ( OH) from hydrogen peroxide present in the cells, is
iron mediated. The presence of iron in rheumatoid synovium is therefore of 
interest.
Rheumatoid arthritis is accompanied by abnormalities in the iron metabolism of 
the body. The plasma 'total iron' concentration level at the onset of inflammation 
IS lowered and there is an increase in iron protein deposition in the synovial 
membranes. The drop in serum iron concentration correlates closely with 
inflammation’». The total iron concentration in rheumatoid synovial fluid has been 
found to be 20-40 x Kk« mol dm-’ «0. Gutteridge et al reported that the "free" 
iron concentration of rheumatoid synovial fluid was 2-3 x 10^  mol dm-’ Most 
of the iron is protein bound, however there is sufficient 'free' iron present in the 
synovium to lead to the formation of deleterious free radical species which lead to 
the degradation of synovial fluid characteristic of rheumatoid arthritis.
1.6.1 The Role o f Iron in the Body
The two principle functions of iron in the body are i) transport of oxygen and ii) 
mediation in electron transfer reactions. Oxygen is transported around the body by 
haemoglobin, an iron-containing protein. Haemoglobin has a molecular weight of 
64,500 and consists of four subunits or haeme groups which contain a central iron 
atom. The haemoglobin has two functions; it binds oxygen molecules to its iron
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atoms and transports them from the lungs to the muscles where they are delivered 
to another iron containing protein, myoglobin, and the haemoglobin also binds 
carbon dioxide produced as waste from the cells and carries it back to the lungs.
Cytochromes are also haeme proteins, present in both plants and animals, which 
are involved in electron transfer chains in the mitochondria. The electron transfer 
is associated with the presence of iron* (Il)-iron (III) redox couple which act as 
electron carriers in various metabolic pathways. The peroxidase and catalase 
enzymes are both haeme proteins. Peroxidases catalyse oxidations by hydrogen 
peroxide, whilst catalases catalyse the disproportination of hydrogen peroxide ( 1 .7 ,
1.8 (S =  substrate)).
HjOj + SHj pgroxidax ) 2 H2O + s (1 .7 )
H2O2  +  H2O2 cataiasc > 2 H2O +  O2  (1.8)
Iron therefore plays a very important role in the body metabolism and a chemical 
system for the storing and transfer of iron is required.
1.6.2 Iroo Stoiage and Transpoft
An average adult male contains about 4.5g of iron. Iron not required in 
haemoglobin and various enzymes is stored as ferritin and haemosiderin. Ferritin 
consists o f a protein shell surrounding an iron core that holds up to 4,5(X) atoms 
of iron per molecule of protein*2. iron enters ferritin as Fe(ii), becomes oxidised to 
Fe(iii) by the protein and deposited inside the core. The ferritin can be converted 
into an insoluble product known as haemosiderin. Iron ingested is taken up by the 
gut, transferred to the circulation and enters the plasma bound to transferrin, a
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carrier protein molecule. Transferrin is a glycoprotein and each molecule has two 
separate binding sites to which iron(iii) attaches itself firmly at physiological pH. 
Tight binding requires the presence at each site of an anion, usually bicarbonate 
(HCO3 *)• 'Vhen the iron is needed, acidification of the environment facilitates the 
release of the transferrin bound iron. Under normal conditions, the transferrin 
present in the human bloodstream is only about 30% loaded with iron on average,
so that the amount of free iron salts in blood plasma would be expected to be 
virtually zero.
1.7 AIMS OF THIS PROJECT
Bone and joint disease, including rheumatoid arthritis, is prevalent in today's 
population as longevity is increased. Rheumatoid arthritis is a chronic and acute 
inflammation of the joints and the onset and course of the disease is not well 
understood. As a result of this, treatment involves, at best, a remission. As yet no 
cure or preventative action has been found. In this project specific low molecular 
weight or 'free' metal ions encountered in bone and joint disease either introduced 
for therapeutic purposes, such as gold and titanium, or present naturally, such as 
iron, will be studied. Their spéciation will lead to a greater elucidation of their 
role and action in the diseased joint environment, and might lead to a greater 
understanding of the disease itself.
Treatment with gold drugs is one of the few therapeutic regimes that can 
produce remission of rheumatoid arthritis. Most of the gold becomes protein 
bound in the body, but a small amount is present as low molecular 'free' gold. 
This gold is probably of vital importance in gold transport systems and helps in 
the achievement of equilibria. There is a need to develop a relatively quick
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qualitative and quantitative analytical method to measure the low molecular weight 
gold from patients undergoing chrysotherapy which involves very little 
pretreatment. This project aims to develop a HPLC method for the determination 
of free gold from the serum and synovial fluid of rheumatoid patients undergoing
gold treatment. This would lead to a better understanding of the action and 
efficacy of gold drugs.
Up until recently it has been thought that titanium alloy implants, introduced 
during surgery after the extraction of broken or badly damaged hip joints, are 
completely inert in the biological environment. However in recent years there have 
been reports o f dark staining of tissue adjacent to the titanium prostheses, noted 
during revision surgery of failed hip implants. This staining is thought to be due 
to titanium. Until now, no work has been done on the spéciation and possible 
complex formation that gives rise to the staining. The aim of this study was to 
determine the possible cause of the dark pigmentation and the possible titanium
complexes formed. A variety of analytical methods were used including FTIR and 
NMR.
A possible cause of rheumatoid arthritis is the destruction and degradation of the 
synovial fluid and connective üssue by highly reactive free radicals. It is known 
that hydrogen peroxide is produced in the cells during inflammation. The 
deleterious hydroxyl radical (-OH) is readily formed from the hydrogen peroxide 
in the presence of low molecular weight iron. There is a deposition of iron in the 
rheumatoid diseased joints and this can accelerate free radical reactions. The 
amount of free' non-transferrin bound iron in rheumatoid arthritis has been 
measured, but to date no investigation has been made of the precise chemical 
nature of the iron. This study aims to investigate the nature of the low molecular 
weight iron present in rheumatoid synovial fluid by means of NMR spectroscopy.
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Understanding the chemical nature of the low molecular weight metal ions 
encountered in bone and joint disease will lead to increased awareness of the 
action of therapeutic agents and any needs to modify them. It will also go some 
way to elucidate the disease itself.
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2.1 ANALYTICAL TECHNIQUES EMPLOYED
A number of analytical techniques have been employed in the analysis of the 
metal ions in biological fluids and tissues relevant to this study. These include 
chiefly, reversed phase HPLC, with the use of atomic absorption spectroscopy 
(AAS) as a means for corroboration, Fourier Transform infrared spectroscopy 
(FTIR) and nuclear magnetic resonance (NMR) spectroscopy. Ultra-violet (UV) 
spectrophotometry was also employed.
The metal ions found in vivo are present in very small concentrations, usually in
/xmol dm-3 quantities. For this reason the analytical techniques used must be very 
sensitive.
A relatively rapid and sensitive analytical method with minimal pre-treatment was 
required for the detection of gold in blood plasma and synovial fluid from 
rheumatoid patients undergoing chrysotherapy. In the following work, separation 
and detection of gold was very effectively achieved by the development of an 
HPLC method which required little pre-treatment, exhibited a high level of 
sensitivity (detection limit l.(X) x 10^ mol dm'^) and was relatively rapid. A UV 
detector was used in conjunction with the HPLC chromatograph. Atomic 
absorption was employed as a corroborative analytical method.
Founer Transform infrared spectroscopy was employed to speciate the titanium 
ions within a piece of dark stained tissue obtained during revision surgery for a 
failed titanium alloy prostheses by comparing the tissue FTIR spectra with spectra 
of synthesised suspected titanium compounds.
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Proton Hahn spin-echo NMR spectroscopy provided a highly effective analytical 
tool to study low levels of metal ions in biological media. It was employed to 
deñne the precise chemical nature of both titanium and iron metal ions as 
encountered in bone and joint disease.
2.2 UQUID CHROMATOGRAPHY
2.2.1 Introduction
The separation of compounds of interest is a vitally important step in chemical 
analysis. The most widely used and successful method of separation is 
chromatography. This technique relies on two mutually immiscible phases being 
brought into contact as one phase (the mobile phase) flows over the other phase 
(the stationary phase). The sample mixture introduced into the mobile phase, 
achieves an equilibrium distribution between the two phases many times as it 
migrates through the column system. These interactions make use of the difference 
of the chemical and physical properties of the sample components.
The separated components emerge in order of increasing interaction with the 
stationary phase. Those components or solutes preferentially distributed in the 
mobile phase elute first, and those more strongly retained by the stationary phase 
elute last. Separation is achieved when one component is retarded to such an 
extent so as to prevent overlap with the zone of an adjacent solute as the sample 
components elute from the column.
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In liquid chromatography (LC) the stationary phase is contained within a column 
and the mobile phase is forced under pressure or by gravity through the column. 
The sample is introduced at the head of the column using a suitable introduction 
system. After passing through the column, the separated components are recorded 
using an appropriate detector.
2.2.2 Development of Chromatography
The first acknowledged chromatographic system was demonstrated by DayS3 in 
1897, when he used a column packed with Fullers earth to separate the 
components of crude oil. However, the discovery of the technique of
chromatography is generally attributed to the Russian botanist Mikhail Tswett^^,
who in 1906 reported the separation of pigments found in green plants
(chlorophyll, xanthophyll, etc.) by means of a calcium carbonate column, where 
the pigments were retained at different levels of the column giving rise to coloured 
bands (Greek; chroma-colour, graphein-to write). Although experimental research 
using chromatography followed, it was not until 1941 that Martin and Synge^^ 
developed a basic chromatographic theory. Other milestones in the advancement of 
chromatography were brought about by other workers. In 1952 James and 
Martin»^ developed gas chromatography and Howard and Martin^^ reported
reversed phase chromatography (RPC) in 1950, so called because the polarities of 
the mobile and stationary phase are reversed. In the late 1960's high pressure 
liquid chromatography (HPLC) was developed by Snyder, Scott and Kirkland^s-^o
where the mobile phase is actually pumped through the stationary phase within the 
chromatography column.
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2.2.3 Classification of Liquid Chromatogiaphy
Liquid column chromatography, LCC, can be classified according to several 
modes of interaction
a) Adsorption Chromatography
Adsorption chromatography or liquid-solid chromatography as it is known, 
achieves separation of the sample components by selective adsorption of the solute 
on to the surface of the stationary phase adsorbent. Silica gel is the most widely 
used adsorbent, although alumina can also be used. The adsorbent possesses active 
sites upon its surface, on to which solute molecules will adsorb to different 
extents. The active sites on the silica surface are hydroxyl groups which can be 
activated by prolonged heating. The exact conditions of activation depend upon the 
nature of the surface hydroxyls. The active sites can be deactivated by controlled 
addition of water or other polar organic solvents.
This technique was the one used by Tswett*^ in 1906, and is usually employed 
for the separation of relatively non-polar organic molecules. Compounds which are 
highly polar can be bound on to the absorbent too strongly, even irreversibly.
b) Liquid-Liquid Partition C h io m ato g r^y
In 1941 Martin and Synge^^ introduced the theory of partition or liquid-liquid 
chromatography (LCC). Separation is achieved by the partitioning of the solutes 
between two immiscible liquid phases, one held stationary on a solid support and 
the other mobile. As opposed to adsorption chromatography in LLC the solid 
support has an inert role and merely provides a large surface area on to which the
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stationary phase is absorbed. The solutes to be analysed are separated by selective 
retention, which results from their different distribution coefficients between the 
mobile and stationary phase.
LLC offers a high selectivity for various solute compounds because of the wide 
range of liquids that can be employed for the stationary phase. NORMAL-PHASE 
LLC involves separation using a polar stationary phase, and a relatively non-polar 
mobile phase. In REVERSED-PHASE LLC the stationary phase is less polar than 
the mobile phase. Reversed-phase LLC is generally used to separate solutes with a 
low water solubility, whereas the normal-phase mode is employed when dealing 
with more polar, water soluble solutes.
c) Bonded Phase Chromatograirfiy (BPC)
Bonded phase chromatography forms a branch of solid-liquid chromatography in 
which organic functions are covalently bound on to the surface of a support, 
usually silica gel. Bonded phases are the most widely used column packings in 
LC, accounting for over 80% use in all high pressure liquid chromatography 
(HPLC) separations. Such stationary phases give rise to high efficiencies, 
selectivity control and reproducible results. The high efficiency obtained is partly 
due to the uniform rigid pore structure and chemical stability of the support, as 
well as to the thermodynamic and kinetic properties of the bonded phase.
Chemically bonded phases can be divided into two main categories:
i) normal phase
ii) reversed phase
The term normal phase describes the use of a polar bonded phase in conjunction 
with a less polar mobile phase. Polar bonded phases are made from silica gel by 
the covalent attachment of a polar organic functional group (e.g an amino, cyano 
or hydroxy group) to the surface of the support (adsorbent). The term reversed
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phase describes a hydrophobic, non-polar stationary phase, which consists, most 
commonly, of octyl (C8) or octodecyl (C l8) hydrocarbon chains, attached to the 
silica support. In the reversed phase mode, the mobile phase used is very polar, 
usually aqueous. 90% of bonded phases are reversed phase.
In 1968 Stewart and Perry^* reported their success in preparing a packing 
material for gas chromatography, made by reacting octadecylchlorosilane with 
silica gel by hydrolytic polymerisation, and suggested its potential use in liquid 
chromatography. It was Halasz and Sebastian^ who popularised chemically bonded 
phases, when in 1969 they reported the preparation of a column packing by the 
esterifícation of silica gel with alcohols, followed by the extraction of the
esterifíed product with methylene chloride. The phase produced was "brush" like, 
the organic functions of the stationary phase, protruding like bristles from the 
silica gel surface. New bonding techniques have developed. Currently, most
bonded phases are prepared by reacting organosilane compounds with the silanol 
(Si-OH) groups on the silica gel.
2.2.4 Classification o f Non Polar Bonded Phases
Silica gel is used in almost all current stationary bonded phases as the support 
matrix. Essentially four types of bonds between an organic moiety and the silica 
gel surface, are used to prepare bonded phases; i) ester type ( s  Si-O-R), ii) 
amino type (=  Si-NRj), iii) carbon type (=  Si-CRj) and, iv) siloxane type ( =
Si-O-Si-CRa) (R = organic groups). The siloxane bonded phase is the most 
commonly encountered phase.
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2.2.4.1 Siloxane Type Bonded Phase (Si-O-Si-CRg)
The siloxane type bond (Si-O-Si-CRj) has become the most widely used bonded
phase. It is formed by the reactions of the surface silanol groups with 
organosilanes of the type:
X2 -Si-R (2. 1)
R = Organic Moiety
Most commonly in the reversed phase bonded preparations R is a linear 
hydrocarbon chain, usually an octadecyl (C,g) or octyl (Cg) chain. One of the X 
substituents must be a reactive group, usually a chloride, even though both may 
be reactive. Methyl groups if present, are used as non-reactive substituents because 
of their small size and the stability of their Si-C bond. Organoalkoxysilane 
reagents can also be used but particle aggregation has been reported with this 
method93. with this method. Siloxane-type bonded phases are hydrolytically stable 
over a pH range of 2-8.5. The siloxane coating can either be made as a 
monomolecular layer, or as a polymerised multilayer, depending on the silanizing 
agent and on the conditions. The two types of coating formed are known as 
monomeric and polymeric phases, respectively.
2.2.S Monomeric Phases
Brush-type phases or monomeric phases as they are more commonly known, are 
used to a greater extent than polymeric phases. The term "monomeric" is used to 
indicate that the surface of the silica is covered with a monomolecular layer of 
hydrocarbonaceous functions, which are attached to the surface via siloxane
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bridges. The phases are prepared by reacting the organosilanes, most commonly 
chlorosilanes, with activated silica. If the reagent is a di- or tri- chlorosilane, 
absence of water is vital in order to avoid crosslinking polymerisation.
With monosubstituted reagents e.g. monochlorosilanes, it is obviously impossible 
for polymerisation to occur and they are therefore the most commonly used 
reagents in the synthesis of monomeric phases. When multifunctional reagents such 
as di and trichlorosilane are used, not all the reactive chloro- groups will react 
with the silica, due to steric hindrance. These residual sS i-C l groups can be 
hydrolysed to form silanols (^Si-O H ). These free hydroxyl groups are 
undesirable, as they can hinder chromatographic separation due to mixed retention 
mechanisms. The reaction should therefore take place in dry solvents to stop 
hydrolysis. The silica should also be heat treated to remove water bound to it. The 
presence of free hydroxyl groups after bonding of the stationary phase, can be 
determined by methyl red adsorption. A red colour is seen in the presence of the 
mildly acidic hydroxyl groups. To reduce significantly the silanols that are 
accessible to the sample components, the bonded phase is treated with 
trimethylchlorosilane (Me3SiCl) or hexamethyldisilazane ((0113)3 SiNHSi (€ 113)3). 
This reaction is known as "endcapping”.
2.2.6  Polymeric Phases
Polymenc phases are formed by the treatment of silica with di- or tri- 
chlorosilanes in the presence of water. The first reaction step is identical with that 
for the preparation of a monomeric phase. The unieacted groups e.g. Cl, are then 
hydrolysed with traces of water present in the reaction mixture. These newly
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formed silanols can then either undergo a condensation reaction with surface 
hydroxyl groups and/or they can react with excess organosilane. In this way a 
cross-linked polymeric phase is produced.
Columns packed with a polymeric packing can suffer from poor reproducibility 
because of the uncontrollable and unpredictable nature of the polymerisation 
reaction.
2.2.7 General Theory o f Chromatography
2.2.7.1 Molecular Interactions
The distribution of a solute between two phases results from the balance of 
interactive forces between the solute molecules and molecules of each phase^^ 
reflects the relative attraction or repulsion that molecules or ions of the two phases 
show for the solute and for themselves. These forces can be polar, arising from
the permanent or induced electric fields associated with the solute and the solvent, 
dispersive or ionic.
2.2.7.2 Diq)ersive Interactions
Van der Waals forces are relatively weak forces that exist between any adjacent
pair of atoms or molecules. The dispersion forces account for a major part o f the 
total attractive energy.
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The interaction occurs due to the formation of a transient dipole between adjacent 
molecules. An alignment of the molecules occurs due to the unequal distribution of 
electrons within the atom or molecule, at any given instant. The attractive 
interaction energy (Eijjj between two atoms i' and j ' as a result of these 
dispersion forces can be expressed as :
(^j)d =  '3/2 +  Ij) (ajofj/r^) (2 .2)
Here Ij and Ij refer to the first ionisation potentials of the atoms i' and j ' ,  r is
the distance between the two atoms and «j and oj are their respective 
polarisabilities.
2 ,2 .1 3  Polar Intmu;tions
Polar interactions can arise from the presence of permanent and induced dipoles 
within the molecule. When two adjacent molecules possess permanent dipoles, 
dipole orientation occurs, in which the positive end of one dipole is positioned 
close to the negative end of the other. For a maximum energy of attraction, 
orientation of the two dipoles should be linear, however thermal motion causes 
this linear arrangement to be disrupted. On average a net attractive energy (EjjJo
«I
occurs between the positive and negative ends of the two dipoles:
(Eij)„ =-2/3 0*i 2 Mj 2 /kTt«) (2.3)
Here ^  and pj refer to the permanent dipole moments of the adjacent molecules i 
and j ,  k is the Boltzmann constant, r the intermolecular distance and T is the
absolute temperature. The forces between two permanent dipole containing 
molecules are known as Keeson forces.
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A molecule i with a permanent dipole can also induce temporary dipoles in 
adjacent molecules j (whether or not j possess a permanent dipole). The net 
attractive energy (Ey)j resulting from this dipole or Debye interaction is given by:
(Eij)i =  -/*i 2 aj /r6 (2.4)
When both molecules i and j have permanent dipoles, the total induction 
interaction is obtained from the above equation by summing the terms of each 
dipole:
■(ji{ 2 aj +  /ij 2 ofj (2.5)
where fi[ and fij are the permanent dipole moments of molecules i and i and
J
and aj are their polarisabilities.
2 .2 .1  A  Hydrogen Bonding
The basis of hydrogen bonding is largely electrostatic, the normally small 0-H  or 
N-H dipole being effectively magnified by the small radius of the hydrogen atom. 
This allows the hydrogen end of the dipole to approach an interacting proton 
acceptor more closely, leading to a smaller value of r and a larger interaction 
energy. The energy of the bond can be determined by the various factors such as 
acid-base character and stereo chemistry. Polar molecules are attracted to hydrogen 
bonded solvents.
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2.2.7.5  Ionic IntraacticMis
Ions or ionic molecules having a net positive or negative charge exhibit ionic
interactions, which are utilised when separating by ion-exchange or ion-pair 
chromatography.
2.2.1.6 Acid-Base ReacticMis
Acid-base or electron donor-acceptor reactions of the form; A + :B ^ A :B  involve 
hydrogen bonding, Lewis acid-base reactions and the combination o f ions to form 
saits or compiex ions. Pearson»’ surveyed the overail scheme of these acid-base 
bonds in terms of the so cailed soft interactions. Hard interactions being regarded 
as piedominanUy electrostatic in character and soft interactions as mainiy covalent. 
The interaction energy E.^ of these various acid interactions can be expressed as:
E.b =E a *  E„ *  -I- C . *-B (2 .6)
Here and Eg * measure the hard (electrostatic) acid and the base strengths
of a given molecule, and * and Cg measure the corresponding soft 
(covalent) acid and base strengths.
The total energy of interacüon of a molecule i, surrounded by phase j, is a sum 
of all the possible interactions: dispersion E j, dipole orientation E„ and induction 
Ej and acid-base type interactions. Thus the totai interaction energy Ejj, between 
non-bonding species can be written as:
Eij = Ed +Eo +Ei -l-EAB (2.7)
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2.2.8 Chromatographic Behaviour o f Solutes
2.2.8.1 R^ention Behaviour
The retention of solute molecules reflects their distribution between the mobile 
and stationary phases. Figure 2.1 depicts the parameters that are measured from a 
chromatogram obtained from the separation of two components.
The volume of the mobile phase needed to carry a solute band from the point of 
injection through the column and to the detector (to the apex of the solute peak) 
is defined as the retention volume, Vr. It may be directly obtained by the 
measurement of the retention time, t^, of the solute. Retention time is defined as 
the time taken for a solute band to elute (at peak height maximum) from the pioint 
of injection. Retention volume may be obtained by multiplying the retention time 
with the flow rate of the mobile phase, F^.
^  Pc (2. 8)
Vm =  tM F (2.9)
Vm is known as the dead volume, and is a measure of the volume of mobile 
phase that is needed for an unretained component to pass through the column, t^, 
is the transit time of a non-retained solute. The adjusted retention volume, Vr ', or 
time, tR* is given by:
Vr ' Vr - Vm or t»' =  to - t,M (2 . 10)
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Figure 2.1 Chromatographic Param^ers
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2.2.8.2  Distribition Coefficient
A solute on entering a chromatography column, distributes itself between the 
stationary and mobile phase. If at some point the mobile phase is stopped, the 
sample components will very rapidly achieve an equilibrium distribution between 
the two phases. In this state the concentration of solute in each phase is given by 
the distribution coefficient, K:
K =  Cc /CM (2 . 11)
Cs and C^, are the concentrations of the solute in the stationary and mobile phases 
respectively. The distribution coefficient determines the average velocity of the 
solute in each zone.
2.2.9  Band Broadening
As a solute migrates along the column, the band width increases as a result of the 
kinetic processes occuring within the column. Whilst working on gas 
chromatography (GC) van Deemter et al^^ attributed this band broadening to three 
factors related to plate height, H, by postulating the van Deemter equation:
H = 2\dp +  2«Dm //* +  2/3 K 7(l+ K ')2  .D^, dfV /D s (2.12)
Stated in its simplified form:
H — A +  B//X +  Cfi (2.13)
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where H is the plate height, fi the average linear mobile phase velocity, and the 
A, B and C terms express the kinetic contributions from eddy diffusion, 
longitudinal or axial diffusion and mass transfer between the mobile and stationary 
phases. Variables such as particle size of the packing, thickness of the stationary 
phase, and the flow rate determine the value of these effects.
2.2.9.1 Eddy Diffusion
Eddy diffusion constitutes the A term in the van Deemter equation, and results 
from the inhomogenecity of flow velocities and path lengths around the packing 
particles.
A = 2\d, (2.14)
dp is the particle diameter of the packing and X is an unspecified constant that is a 
function of packing uniformity and column geometry. X usually has a value of 1-6.
If the packing is anything less than perfect, the flow paths of the solute molecules 
will be of unequal length. So some molecules of a single species, will flow close 
to the column wall, where the packing density is relatively low, whilst other 
molecules will pass through the more tightiy packed centre of the column, at a 
lower velocity. Therefore molecules following an easier flow path will elute 
sooner than ones following a more difficult flow path, leading to band broadening.
The A term is therefore a measure of how well a column is packed and it can be 
minimised by making the mean particle diameter, dp as small as possible and by 
obtaining a uniformly packed column.
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2.2.9.2 Longitudinal Diffusion
The B term in the van Deemter equation accounts for longitudinal or axial 
diffusion, that is random molecular migration. It is expressed as:
B =  2 iD M (2.15)
where i  is known as a tortuosity constant which accounts for restriction to 
diffusion by particles and ranges between 0.01 and 1 .0. is the solute diffusion 
coefficient in the mobile phase and is concerned with the diffusion of the sample 
in the mobile phase. High diffusion rates in the mobile phase make the solute 
bands disperse axially along the column, especially at low mobile phase velocities, 
which leads to band broadening.
In the van Deemter equation B is divided by the mobile phase velocity, B/^ So to 
minimise the B term, the mobile phase velocity should be as high as possible and 
the diffusion rate, D^, should be low.
2.2.9.3 Mass Tiansft^
The C term in the van Deemter equation is expressed as:
C =  2/3 K 7(l +  K')2 . Dm df 2 /D j (2.16)
where K’ is the capacity ratio which is related to the distribution coefficient, df is 
the film thickness of the stationary phase coating and Dg is the diffusion 
coefficient of the solute in the stationary phase. The C term describes dispersion
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due to slow mass transfer which occurs because of the slow equilibrium of the 
solute between the mobile and stationary phases. As solute molecules move 
through the column, they suffer random displacements (changes in position) away 
from the centre of this molecular assembly. Displacements in the direction of flow 
are responsible for band spreading, since these displacements can be regarded as a 
number of forward and backward random walks, relative to the band centre.
To minimise the C term, a high diffusion coefficient term is desirable, and so is 
a thin film coating, df. However if the film thickness is decreased so is retention.
In the van Deemter equation, the term C is multiplied by the average linear 
velocity (C/t). Therefore as slow a linear velocity as possible should be used to 
minimise the C term. So terms B and C contradict each other as to the optimum
linear velocity for minimising the terms. This is indicated in the HETP graph in 
Figure 2.2.
Taking into account all the terms, the best overall linear velocity is (see 
figure 2.2). At (flow rate approximately 0.1 ml/min) maximum efficiency is 
achieved. However as this minimum (H) region is quite broad for a usual LC 
column, efficiency can be traded for speed, and the work can be carried out at 
higher /x values (of around 1 ml/min flow rate).
For well packed columns the A term is 1, B is 2 and C is about 0.05.
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Figure 2.2 Van Deeimer H/u Plot (HETP) in Liquid Chromatography
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2.2.10 HPLC Instnimentadoo
The general instrumentation for HPLC consists of a solvent pump, an injection 
device to introduce the sample onto the column, the separation column, and a 
detector with recorder readout. The high pressure pumping system delivers the 
mobile phase solvent from the solvent resevoir to the column through stainless 
steel tubing and fittings (Figure 2.3). The stainless steel columns usually used for 
analytical separations have small internal diameters (2 to 5 mm).
PMmP
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Figure 2.3 Schematic Diagram of HPLC Apparatus 
2.2.10.1 HPLC Detectors
Detectors which can be used in liquid chromatography include ultraviolet 
(UV)/visible, fluorometric, infrared (IR), and electrochemical (EC) detectors and 
differential refractometers. These detectors can be catagorised as being either bulk 
property or specific property detectors. Bulk property detectors, typified by the 
refractive index monitor, compare an overall change in a physical property of the 
mobile phase with and without the eluting solute. Although universal, this detector
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tends to be relatively insensitive. The specific property detectors respond to a 
physical property of the solute not exhibited by the mobile phase. Solute property 
detection is roughly 1000 times more sensitive than mobile phase detection. 
Ultraviolet/visible absorption, fluorescence and electrochemical detectors are 
examples of specific property detectors. Precolumn and postcolumn derivitisation 
expands their applicability.
The UV/visible detector can either be a fixed wavelength detector, which operates 
at wavelengths of 240 or 280 nm, or a variable wavelength detector. The fixed 
wavelength detector is the most widely used in LC. Its main advantages are its 
relatively low cost, high sensitivity for compounds of both chemical and 
biological interest that absorb light in the UV region and its insensitivity to 
changes in temperature, flow rate and mobile phase composition. The variable 
wavelength detector operates by rotating a diffraction grating to the appropriate 
incidence angle to give the desired wavelength. The advantages of this detector are 
the availability of a wide range of wavelengths, the ability to alter wavelengths 
without changing filters or lamps, and the ability to operate at wavelengths below 
254 nm. All compounds that have one or more double bonds, or have unshared 
unbonded electrons (e.g aromatics and compounds with carbonyl, thiocarbonyl, 
nitroso and azo groups) will absorb in the UV region.
Fluorometric detectors are sensitive to compounds that are inherently fluorescent 
or that can be converted to fluorescent derivatives by either chemical 
transformation of the compounds or by the coupling at specific functional groups 
with fluorescent tagging reagents. Turbidity of the sample will present a problem 
to fluorescence.
Infrared detectors are particularly useful when the compound of interest is not 
active in the UV region.
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Electrochemical detectors can be used where the compound of interest can be 
oxidised at a suitable electrode present in the detector. Once the operating 
potential has been chosen, chromatograms are plotted showing current as a 
function of time. Compounds typically detected by electrochemical means include 
aromatic amines and their derivatives, ascorbic and uric acid, and phenolics and 
carboxylic acids.
The differential refractometer detects differences between the refractive indexes of 
the pure solvent and of a solution of the solute of interest in the solvent. The 
response is affected by small changes in the solvent composition, flow rate and 
temperature.
In general the signal output from the detector is amplified before it is fed to a 
suitable automatic recording device, usually a strip chart potentiometric recorder, 
where the signal is plotted against time.
2.3 ELECTROMAGNETIC RADIATION
Spectroscopy involves the measurement and interpretation of electromagnetic 
radiation absorbed or emitted when molecules, atoms or ions of a substance 
transfer from energy level to another, in absorption spectroscopy this involves 
excitation from the ground state to an excited state. Each substance has a 
characteristic interaction with the electromagnetic radiation.
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2.3.1 Propertíes o f Electroinagiietíc Radiation
A beam of light may be viewed as a collection of photons of energy that move at 
the speed o f light. A photon has both wave and particle properties. A photon 
originating from a point in space, radiates from that point in the form of a 
spherical wave which has periodic maxima perpendicular to its direction of travel. 
The distance between two maxima is deemed the wavelength (\). The frequency 
(v) is the number of waves that pass a given point in a unit length of time.
The energy of light is given by Plancks equation:
E =  hv =  hc/A (2.17)
where c is the speed of light in a vacuum (3.(X) x lO« m sec-i ) and h is Plancks 
constant. The shorter the wavelength of the radiation the higher its energy.
Interaction with matter occurs throughout a broad range of radiations to give the 
electromagnetic spectrum (Figure 2.5). The radiations all travel with the speed of 
light but differ in their wavelengths, frequencies and the effects they produce. 
Radiation in the ultraviolet (UV) region is high energy and can excite electrons 
away from the nucleus to an excited state. Infrared (LR) radiation has only enough 
energy to excite vibrational and rotational energy. Microwave radiation is involved 
with changes in electron spin states and the low energy radio waves are involved 
with the flipping of nuclear spins^7,98^
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2.3.1 Properties o f Electromagiietic Radiation
A beam of light may be viewed as a collection of photons o f energy that move at 
the speed of light. A photon has both wave and particle properties. A photon 
originating from a point in space, radiates from that point in the form of a 
spherical wave which has periodic maxima perpendicular to its direction of travel. 
The distance between two maxima is deemed the wavelength (\). The frequency 
(v) is the number of waves that pass a given point in a unit length o f time.
The energy of light is given by Plancks equation:
E =  hv = hc/A (2.17)
where c is the speed of light in a vacuum (3.00 x lO« m sec-i ) and h is Plancks 
constant. The shorter the wavelength of the radiation the higher its energy.
Interaction with matter occurs throughout a broad range of radiations to give the 
electromagnetic spectrum (Figure 2.5). The radiations all travel with the speed of 
light but differ in their wavelengths, frequencies and the effects they produce. 
Radiation in the ultraviolet (UV) region is high energy and can excite electrons 
away from the nucleus to an excited state. Infrared (IR) radiation has only enough 
energy to excite vibrational and rotational energy. Microwave radiation is involved 
with changes in electron spin states and the low energy radio waves are involved 
with the flipping of nuclear spins57.98.
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2.4 INFRARED SPECTROSCOPY
The IR region of the electromagnetic spectrum crosses the wavelengths between 
0.7 and 500 fxm or in wave numbers (lA) between 14,000 and 20 cm-K Infrared 
spectroscopy is concerned with the excitation of mechanical motions within a 
molecule. These motions involve stretching, or deformation of bonds. These 
observed motions are rarely pure and due to singular vibrations. Usually coupled 
motions have to be observed. These fall into three groups: i) coupling between 
two fundamentals e.g symmetric and asymmetric stretches of a C-H bond, ii) 
overtones and combinations iii) Fermi resonance; a combination of coupling 
between an overtone and a fundamental.
As a large number of vibrations occur simultaneously, a complex absorption 
spectrum is obtained, which gives an indication of the overall configuration of the 
atoms as well as the functional groups present within the molecule.
These vibrational motions are quantised and at room temperature the molecules 
will be present mostly in the lowest vibrational state. However when the molecule 
absorbs light of an appropriate wavelength and energy, it will become excited and 
will move to a higher energy level. In IR spectrophotometry, the absorption of 
such a quantum of energy can only occur if the dipole moments differ in the two 
vibrational energy levels. When bonds stretch or bend in a vibrating molecule the 
dipole moment may vary. This oscillating dipole shakes the electromagnetic field 
into oscillation and so radiation may be absorbed. Therefore only vibrations that 
are accompanied by a changing dipole moment can be excited by electromagnetic 
radiation. The necessity for absorption of a vibrational quantum to be accompanied
by a change in dipole moment is known as the selection rule. Then the molecule 
is said to be infrared active.
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An infrared spectrum is obtained by plotting the wavelength against per cent 
transmittance of the sample. Absorption of light is manifested as a trough in a 
curve. Zero transmittance corresponds to 100% absorption of light of that 
wavelength. Of the IR ranges, the mid-infrared region, also known as the 
Tingerprinf region (1300-650 cm-i) is the most valuable in compound 
identification, as absorption in this region is highly characteristic of certain 
molecules.
2.4.1 Fourier Transform Infrared (FTIR) Spectroscopy
An FTIR spectrophotometer, consists of three main parts; a radiation source, an 
optical system and a detector (Figure 2.4). A half reflecting mirror splits the 
beam from a light source (a glowbar) into two equal parts. The two beams 
traverse different paths, being reflected by different mirrors, before coming 
together again just before passing through the sample and into the detector. The 
distance travelled by one of the beams is oscillated by moving one of the mirrors 
(M4).
If the lengths of the two optical paths are identical then there will be no phase 
difference between the beams and they will combine constructively. If there is a 
difference between the two optical paths, the beam may recombine destructively. 
For different interferometer path lengths, the amplitude of the recombined signals 
will depend on the frequency and distance moved by the mirror M4. For instance 
low frequencies will give destructive interference, with phase shifts of the order of 
about 100 , with large movements of the mirror. High frequencies need only a 
small movement of the mirror M4 to achieve the same interference. The beam 
focused on the sample is a complex mixture of modulation frequencies, which on 
passing through the sample is collected by the detector. The detector signal is
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sampled at precise intervals during the scan. A reference laser beam is passed 
through the system to oversee the whole process by controlling the sampling rate 
and the mirror velocity. The resulting signal is Icnown as an interferogram and 
contains the information necessary to construct a spectrum using a mathematical 
process known as a Fourier transformation.
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Figure 2.4 Diagram of Infrared Fourier Transform Interferometric Spectrometer
FTIR has five main advantages over convential infrared techniques; 
i) mechamcally there is only one moving part, M4,
u) Jacquinofs advantage - there are very few optical surfaces and no gratings or 
prisms which leads to fewer monochromator losses,
111) FeUgett's advantage - aU the wavelengths are detected simultaneously. At any
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one wavelength the detector has more time to accumulate signals,
iv) The computational power offers signal averaging - as the signal to noise ratio 
(S/N) is proportional to the square root of the number of scans. Therefore 
four scans give a half the noise. Usually 32 scans are made (approximately 
60 seconds) to produce an averaged interferogram.
v) Connes' advantage - the FTIR spectrophotometer is continually calibrated 
with reference to the laser beam, therefore wavelength accuracy and precis­
ion is excellent.
2.5 ATOMIC ABSORPTION SPECTROSCOPY (AAS)
Atomic absorption spectroscopy is based on the absorption of ultraviolet or 
visible light by gaseous free atoms’». The compound to be analysed must first 
absorb enough energy to be vaporised, and to form a molecular gas, where the 
molecules have dissociated to form free atoms. An absorption spectrum is obtained 
when the free atoms absorb radiant energy at characteristic wavelengths.
In order to vaporise the sample, the solution is aspirated into a flame, where the 
solvent is evaporated and the sample compounds become thermally decomposed 
and converted to a gas of individual free atoms. The free atoms are mostly in a 
ground state and absorb radiation from a light source when the radiation 
corresponds exactly to the transition of the element of interest from the ground 
state to a higher excited state. Some of the light will be absorbed by the free 
atoms of the sample, and the rest will pass through. The spectral line of interest is 
isolated from the emerging beam by a monochromator and the ratio of the
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intensity of the line to that of its source is measured by a photocell or 
photomultiplier. Therefore the ratio between the incident beam (Pq) and the 
transmitted beam (P) is measured.
A hollow cathode lamp containing the element to be analysed is used as the light 
source, so that the atoms of the analyte metal absorb at exactly the same 
wavelength emitted by the light source. As the cathode lamp has narrow band 
emissions, virtually complete specificity for the element is provided.
Therefore there is hardly any interference from the spectral lines of other 
elements.
The amount of light absorbed by the sample depends on the number of atoms 
found in the path of the light. Provided that the flame is hot enough to convert the 
aspirated solution to free atoms, the light absorbed is almost independent of the 
flame temperature and the wavelength of absorption.
If the flame conditions are kept fairly constant as well as the rate of sample 
aspiration, then the absorbance (log Pq/P) is directly proportional to the 
concentration o f a given metal in the sample.
2.5.1 Instrumentation
An AA spectrophotometer consists of a light source (the hollow cathode lamp), a 
bumer-nebuliser and a monochromator and detector (Figure 2.5). The hollow 
cathode lamp is evacuated, but contains some argon or neon gas. The cathode 
contains the element to be determined e.g if gold is to be determined a gold 
cathode is used. A high voltage of about 400 volts ionises the atoms of argon.
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which bombard the cathode. This bombardment leads to the expulsion of the metal 
atoms into the atmosphere of the tube, where they collide and become excited, 
emitting light at wavelengths that are characteristic of the cathode metal.
Figure 2.5 A Double-beam Atomic Absorption Spectrometer.
The bumer-nebuliser produces a flame, most commonly an air-acetylene flame. 
Some metals are refractory and are difficult to convert to gaseous atoms. Among 
these are boron and titanium, as they form very strong metal to oxygen bonds 
which are difficult to decompose thermally. This problem is overcome by the use 
of a fuel rich oxy-acetylene or nitrous oxide-acetylene flame. The height of the
flame and the rate of aspiration can be adjusted to achieve maximum sensitivity 
for particular elements.
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Another way of producing gaseous free atoms is by the use of an electric 
furnace, where no flame is used. In this technique a few microlitres of the sample 
are placed in a graphite tube, which is heated electrically until the gaseous free 
atoms are produced. A beam of monochromatic radiation from the hollow cathode 
lamp traverses the tube and is partly absorbed by some of the gaseous atoms. The 
sample element is analysed and calculated as in the flame atomic absorption 
spectrophotometer.
The graphite furnace removes the requirement for the nébulisation of the sample 
as occurs in flame AA. This is not a very efficient process and the free gaseous 
atoms only stay in the beam for a fraction of a second. However, liquid samples 
need three heating stages. At the first stage the solvent is removed, the second 
stage involves the ashing of the sample, and at the final heating stage the analyte 
is converted to free gaseous atoms.
The sensitivity of the graphite furnace depends on the metal being analysed, but it 
is usually achieves a greater sensitivity than the flame A A.
The monochromator selects the spectral line of interest, as the lines of the source 
are narrow and there is almost zero background interference.
The concentration of the element of interest in the sample is obtained by the 
preparation of a calibration curve from serial dilutions of a standard solution of 
the metal salt of interest.
The accuracy and precision of the AA spectrophotometer depend on the element 
analysed.
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2.6  NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY
Nuclear magnetic resonance (NMR) spectroscopy allows elucidation o f the 
configuration of molecules by investigating nuclear spins when the molecule is 
placed in a strong magnetic field. In the magnetic field, the nucleus can have 
quantised nuclear energy levels, corresponding to certain orientations of the spin 
magnetic moment. Absorption of radiation is detected when the difference between 
the nuclear levels corresponds to absorption of a quantum of radiation. In NMR
the sample is placed in a magnet and the nuclei in the molecule generate a bulk 
macroscopic magnetisation (Figure 2.6).
Saaple Tube
Figure 2.6 A Schematic Diagram of an NMR Spectrophotometer.
2.6.1 General Principles o f NMR
The nucleus of certain isotopes, for example protons in a water sample, possess 
an intrinsic spinning motion around their axes, which wiU interact with an applied 
magnetic field. The nuclear spins will either align with the magnetic field, which
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is the more stable configuration, or against it, which is less stable as energy has 
to be absorbed to flip over the proton. The proton has a spin quantum number, 
1=1/2, which in a magnetic field generates two energy levels (Figure 2.7). These 
energy levels can be characterised by the nuclear spin number m|, and they are 
separated by the difference in energy states 5E. The difference between the energy 
states is dependant upon the magnetic field:
5E = hTBo/2T (2.18)
where t  is the magnetogyric ratio and Bq is the magnitude of the applied magnetic 
field.
The lower energy state, where the magnetic moment is parallel to the applied 
magnetic field, Bq, has the magnetic spin number m] = +1/2 , and is usually 
known as the a state. The upper energy state, 6, in which the magnetic moment is 
antiparallel to Bq, has the magnetic spin number m] =  -1/2.
Transitions can occur when the gap between the energy levels is exactly the same 
as the in coming frequency (E=hv).
The frequency of observation can be expressed as:
V =  i Bq/2t (2.19)
V is the resonant frequency in hertz. The difference in the magnetogyric ratio t, 
gives different observation frequencies for differing nuclei, v for carbon 13 (i3C), 
is one quarter of that for protons, »H. Therefore a signal for is seen at a
frequency of 50.3 MHz, whilst for a proton it is seen at 200 MHz in the same 
magnetic field.
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BFigure 2.7 Energy level diagram for spin with I= 1/2 in a magnetic field B
In proton NMR, the frequency of the absorption depends on the magnetic and 
electric environment of the nuclei. These environments generally determine the 
position of the signals in an NMR proton spectrum. The electrons around the 
proton nucleus begin to precess when placed in an applied magnetic field Bq. This 
motion induces a magnetic field which opposes the applied magnetic field. As a 
result, the net magnetic field experienced by the proton is said to be "shielded" 
and absorption occurs upfield. If the induced magnetic field enhances the applied 
field, then "deshielding" occurs and the absorption is downfield. These movements 
in absorption are known as chemical shifts. As a general rule, as the
electronegativity of the surrounding atom increases, so the electron density 
decreases and deshielding occurs.
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The appearance of a resonance in proton NMR is influenced by the neighbouring 
hydrogen nuclei of the molecule. Resonances apf>earing as peaks have the form of 
doublets, triplets etc.; that is to say that peak splitting occurs. This phenomenon 
arises from the magnetic field that is associated with each individual neighbouring 
spinning proton. These magnetic fields will alter the total magnetic field 
experienced by another proton. The signal will split into two, giving a doublet if 
influenced by one neighbouring proton, and if influenced by two protons it will 
split into a triplet.
The magnetic field experienced by the secondary proton is influenced by the 
adjacent tertiary proton (Figure 2.8). By way of shared electrons, the magnetic 
field will be increased when the tertiary proton is aligned with the field, and 
decreased when aligned against it. As a result the absorption by the secondary
proton is shifted slightly downfield for half the molecule and for the other half it 
is shifted upfield.
H
Tertiary Proton
HC------C—
H Secondary proton
Figure 2.8 Positions of Secondary and Tertiary Protons
If the tertiary proton has a 6-spin, the effect is as if the total magnetic field 
experienced is greater than that supplied by the applied magnetic field generated 
by the NMR instrument. Therefore less applied field is needed to achieve a 
resonance, than in the absence of the tertiary proton and a slight downfield shift is 
experienced. Only half of the tertiary protons have a B-spin, the rest having an a- 
spin. As a result these molecules feel as if the magnetic field is weaker at the
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secondary proton than that of the applied field. A greater magnetic field must 
therefore be supplied by the NMR spectrophotometer. This results in an upfield 
shift. The secondary and tertiary protons are said to be coupled. For one half of 
the molecule, the absorption for the secondary proton is shifted slightly downfield, 
and for the other half of the molecule it is shifted slightly upfield. The signal is 
therefore split into two peaks giving a doublet of a 1:1 intensity. Similarly, the 
magnetic field experienced by the tertiary proton is influenced by the spin of two 
neighbouring protons and the NMR signal splits into a triplet if intensity 1:2:1.
2.6.2 Pulse NMR
The proton NMR spectra of biological samples usually exhibit broad overlapping 
resonances attributable to the presence of relatively immobile macromolecular 
species such as proteins. Application of a pulse NMR technique, suppresses the 
broad resonances, giving a clearer NMR spectrum with well resolved resonances 
arising from the low-molecular mass components of the sample’ .^
The pulse NMR technique involves disturbing the system from equilibrium by the 
application of a pulse and then following the response of the system to the 
disturbance. The magnetisation of a sample is achieved by application of a 
magnetic field. This magnetisation can be perturbed by a second field oscillating 
with the appropriate radiofrequency. This disturbance of the magnetic field 
generates the nuclear magnetic spectrum. In continuous wave (CW) NMR the 
disturbance is measured as either the radiofrequency is varied or the field is swept, 
only one single frequency being excited and at the same time detected. In pulsed 
FT NMR, the entire spectrum is excited by a pulse of radiofrequency energy, and
the response of the sample to the pulse is measured as a function of time and is 
converted to the frequency domain by a computer*«>.ioi.
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The NMR pulse technique is best described by use of a vector diagram (Figure 
2.9).
Figure 2.9 Vector Diagram Showing Behaviour of the Bulk Magnetization M a) 
at Equilibrium, and b) after Perturbation by a Pulse
The net magnetisation of the sample (M) will align with the magnetic field 
initially. The applied field (Bq) will be in the z direction. The net magnetisation 
can be moved from its equilibrium, by a second magnetic field or pulse, to the xy 
axis. This NMR signal can be detected. However the net magnetisation will return 
to its equUibrium position and the signal will gradually decay. This signal is called 
a free induction decay (FID). In order for the spin to return to equilibrium, there 
must be interaction between the spins and the surroundings or ”lattice", which 
leads to die loss of excess energy. The time for the spin system to return to the 
equilibrium by this method is known as the spin-lattice or longitudinal (i.e along 
the z axis) relaxation time (T,) and is of the order of seconds. When the net 
magnetisation is disturbed from equilibrium, it may also have components in the 
xy-plane which will also relax to zero. Magnetisation in the xy-plane may also be
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lost by additional processes which cause the xy components to fan out or dephase. 
These processes do not necessarily need an energy change, so the xy relaxation 
rate may be faster than the z relaxation. The time for the xy relaxation to occur 
is known as the spin-spin or transverse (perpendicular to z axis) relaxation time 
(T2).
2.6.2.1 Hahn Spin-Echo
The pulse sequence most commonly used is the two pulse Hahn spin-echo 
experimenti®2. in its simplest form it can be written as:
t /2 - tn - t  - tn - Echo (2.20)
A schematic representation of the Hahn spin-echo is shown in Figure 2.10 by 
using vector diagrams.
Figure 2.10 Vector Diagram of Hahn Spin Echo Sequence
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If we consider a sample with resonance at the z axis. The chemically identical 
spins of the sample are found in different parts of the the NMR tube, and as such 
will experience different affective magnetic fields. Field inhomogeneity will 
therefore result and the spins will precess at a range of frequencies, rather than at 
a single frequency. A t /2 or 90° pulse is applied to the sample and the 
magnetisation vectors are tipped into the xy-plane, where due to the loss of phase 
coherence the vectors fen out. The main contributing factors to the dephasing are 
the loss of phase coherence from spin-spin relaxation and the inhomogeneity of the 
applied magnetic field (B„). The fanning out occurs as the nuclei precess at 
different rates within the sample, some slower and some faster. The signal 
observed will result from the vector sum of the components, but as the 
components fen out the vector sum decreases and the net signal decays rapidly. A 
»  pulse (180°) is applied after a time delay, to. This has the effect o f rotating all 
the magnetisation vectors by 180° about the y axis. The magnetisation will be in 
the xy axis as before but it will now be displaced from the -y axis by an amount 
which dqiends on the time delay, t^, and the precession frequency. However, as 
the magnetisation is still precessing in the same direction as before, it is now 
moving towards the -y axis. After a second identical time delay (tp), the 
magnetisation will converge and refocus at the -y axis. The vector sum and the 
resulting signal intensity will increase to form an echo of maximum amplitude at 
the moment when the second time delay t^ equals the first time delay. After that 
moment, the signal will decay again, but at the peak o f the echo, when the signal 
is collected, all effects of field inhomogeneity, will have been eliminated.
Resolution o f the NMR spectrum is also enhanced by the Hahn spin-echo 
technique due to the fact that different molecules have different spin-spin 
relaxation times (Tj). High molecular weight molecules usually possess short spin- 
spin relaxation times (Tj) compared with the T j value of smaller, more mobile
76

CHAPTER 3
THE DEVELOPMENT OF AN ANALYTICAL METHOD FOR 
THE DETECTION OF GOLD (I) PRESENT AS THE ANTI­
RHEUMATIC DRUG DISODIUM AUROTHIOMALATE BY
HPLC
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3.1 INTRODUCTION
About 5% of the total circulating gold present in rheumatoid arthritis patients 
undergoing chrysotherapy is present as "free" gold, or gold that is unbound to 
protein. This unbound gold could play an important part in the attainment of an 
equilibrium of the gold within a number of biological protein binding sites, and 
could also play a part in transportation processes and, as such, needs to be 
accurately quantified by a reliable method. In this chapter a procedure is sought, 
in which gold present in the drug myocrisin, can be complexed, in order to form 
a stable compound that can be analysed, quantified and standardised by reversed- 
phase HPLC. Complexing with the reagent dithizone, as well as with cyanide is 
carried out to this purpose.
3.1.1 Dithizone as a Complexing Agoit
Dithizone, also known as 1,5-diphenylthiocarbazone, was first prepared by Emil 
Fischer in 1882, who remarked on the compound's ability to form strongly 
chelated complexes with many heavy metals. FischerJ03 carried out extensive work 
on dithizone and utilised its heavy metal complex forming properties to detect and 
determine trace levels of metals. Dithizone has been used for the determination of 
trace levels of gold both by extractive t i t r a t io n w h e r e  the end point is indicated 
by colour change, and by spectrophotometryios. this work the complexation and
extraction of trace levels of gold (I) by dithizone, from standard solutions of the 
anti-arthritic drug disodium aurothiomalate have been attempted. Dithizone was 
used to form gold (I) dithizonate which when extracted and reconstituted can be 
introduced onto a HPLC column, where it was separated out and detected at the 
appropriate wavelength by an UV detector. Standard work was done with a view
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to formulating a method for the quantification of the unbound ("free") gold that is 
present in the biological fluids of rheumatoid arthritis patients undergoing gold 
drug therapy.
Dithizone is a violet-black solid which is soluble in most organic solvents such as 
chloroform and carbon tetrachloride. Two main structures have been proposed for 
dithizone; namely a thione and a thiol form (Figure 3.1). Dilute solutions of 
dithizone are intensely green, whilst more concentrated solutions are dichoric (red 
in transmitted, green in reflected light).
S = C
/
N = N —CgHj
\
NH— N H -Q H j
SiF-C
%
N = N — C J l6"5
N — N H -C ^ h ,
a) b)
Figure 3.1 The a) Thione and b) Thiol Structures of Dithizone
When an organic solution of dithizone is shaken with an aqueous solution of a 
reacting metal, a metal dithizonate complex is formed. The dithizonate is usually 
formed in the organic layer, to which it imparts a violet, red, orange or yellow 
colour depending on the metal involved. The organic layer can be removed, 
evaporated and reconstituted to extract the metal dithizonate.
The metal can displace either one or both of the acidic hydrogens of the dithizone 
to give the keto (or primary) dithizonate, or the enol (or secondary) dithizonate.
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3.1.2 Formation o f Dicyanoaurate
The linear complex ion dicyanoaurate [Au(CN>2]- is a very stable gold (I) 
complex. It has been r e p o r t e d 107 that tobacco smoking produces an increased 
uptake of gold by blood cells of patients treated with aurothiomalate; this effect 
being due to the inhalation of cyanide. Studies*®* indicate that cyanide converts the 
aurothiomalate to dicyanoaurate which is rapidly taken up by the cells. Graham et 
ii/109 earned out *H and NMR and UV spectroscopic studies to elucidate the 
interaction of cyanide with aurothiomalate, and reported that excess cyanide levels 
led to the sole production of [Au(CN)2]-. Haddad et a/**® detected trace levels of 
gold (I) as its cyano complex by ion-interaction reversed-phase HPLC. UV spectra 
of the dicyanoaurate give rise to peak maxima at 209.5, 228,and 239 nm***.
Since cyanide forms such a stable complex with gold (1) and one, moreover, 
which is active in the UV region, in this work, the formation of dicyanoaurate, 
from aurothiomalate in the presence of excess potassium cyanide has been utilised 
to detect low, biologically relevant concentrations of gold (I) by reversed-phase 
HPLC with UV detection. An attempt to standardise the method is carried out 
with a view to its use on appropriate RA biological samples.
3.2 MATERIALS AND METHODS
3.2.1 Materials
The disodium aurothiomalate used was purchased from Rhone-Poulenc (Dagenham, 
Essex). All solvents were of HPLC grade and were purchased from BDH 
Chemicals (Poole, Dorset).
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Chromatographic experiments were performed using a Philips PU 4100 liquid 
chromatograph pump in conjunction with a Philips PU 4110 ultraviolet/visible 
detector. Electronic absorption spectra were recorded on a Philips PU 8740 
ultraviolet/visible scanning spectrophotometer. Standard quartz cells (1.0 cm^ 
pathlength) were used for these measurements.
3.2.2 Dithizone Experiments
The HPLC column used was a reversed phase C18 Spherisorb 5 ODS with an 
i.d. 4.5 mm and of a length of 250 mm. The solutes were introduced onto the 
column using a Rheodyne 7125 valve fitted with a 10 /xL injection loop. The 
absorbance of the emerging eluant was monitored at 450 nm. The mobile phase 
employed was 60:40 (v/v) acetonitrile (ACN) : citrate/acetate buffer. The citrate / 
acetate buffer was of a pH of 4.75 and contained sodium citrate of a concentration 
of 3.00 X 10-2 mol dm-3 and sodium acetate of a concentration of 2.72 x 10-2 mol 
dm-3. The flow rate was l.(X) ml/min unless otherwise stated.
The signal from the photometric detector was recorded on a ChemLab CH-4(X)2 
chart recorder. The chart speed was normally 0.5 cm/min unless otherwise stated. 
A full scale deflection of 10 mV was generally employed.
3.2.2.1 Spectrophotomeric TitraticMi of Dithizone with Disodium Aurothiomalate
The reaction of the dithizone with disodium aurothiomalate was followed by 
means of a spectrophotometric titration. A standard solution of dithizone (5.(X) x 
10-5 mol dm-3) was prepared in the mobile phase (60:40 (v/v) acetonitrile: citrate/ 
acetate (pH 4.75)). To 2.00 mL of the dithizone solution, ten successive 50.0 /jlL
82
aliquots of disodium aurothiomalate (5.00 x 10-5 mol dm*3) were added. After the 
addition of each aliquot, a UV spectrum was run in overlay mode, scanning from 
230-670 nm. The final ratio of dithizone to disodium aurothiomalate was 4:1.
3.2.2.2 Extraction of Au (I) with Dithizone
An aqueous stock solution of disodium aurothiomalate containing 1.00 x 10-3 mol 
dm-3 gold was prepared in degassed sodium hydroxide (1.00 x la ^  mol dm-3). By 
serial dilutions a series of aurothiomalate standard solutions at concentrations of 
5.0, 10.0, 25.0, 50.0, 1(X).0, 250.0, and 5(X).0 x 10-  ^ mol dm-3 were also 
prepared in 1.0 x 10-2 mol dm-3 NaOH. The aqueous aurothiomalate standard 
solutions (1.00 ml) were added to equal volumes of dithizone prepared in 
chloroform (1.00 x 10-3 mol dm*3). The dithizone solution was initially dark green 
in colour. The two layers which formed were rotamixed for 20 minutes in glass 
stoppered test tubes. In the lower (chloroform) layer, a gradual colour change 
from dark green to deep red was noted. At high aurothiomalate concentrations the 
chlororform layer was deep red in colour and at low aurothiomalate concentrations 
the chloroform layer remained virtually unchanged in colour (dark green). 
This procedure was earned out with the addition of a further two l.(X) mL 
aliquots of dithizone to the aurothiomalate solution. The combined chloroform 
layers (total volume 3.00 mL) were evaporated to dryness under an atmosphere of 
nitrogen at ambient temperature. The residue was then reconstituted in 500.00 /xL 
of the mobile phase and injected onto the column. Reconstituted samples with a
high gold (I) concentration were yellow in colour, whilst samples containing a 
large excess of dithizone were green.
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A control sample was prepared by the same method, where sodium hydroxide
solution (1.0 X 10-2 mol dm-2) was used instead of the disodium aurothiomalate 
Standard solutions.
3.2.2.3 Ditfaizooe SpectrophoCometric Results
The spectrum of the dithizone solution displays two major peaks; one at 474 nm 
and one at 596 nm (Figure 3.2, i « g e ^ ) .  The presence of these two absorption 
bands in the spectrum of dithizone points to the existence of two tautomeric 
forms; the thione form 596 nm) and the thiol form 474 nm). The
dithizone solution probably contains the thiol and thione forms in a tautomeric 
equilibrium (Figure 3.3).
H S - C
N = N —C<jH5 , N = N — CM6"5
N  NH—CgHj NH— NH— C.H6"5
Figure 3.3 Tautomeric Equilibrium of Dithizone
Results o f the spectrophotometric titration show that with the addition of each
successive aliquot o f disodium aurothiomalate the peak at 593 nm diminishes in
intensity (Figure 3.4). At the final aliquot addition (1.00 x 10-5 mol dm-3 
aurethiomalate, 4.00 x Ilk* ^  ^
thione form nearly disappears (Figure 3.5), indicating the complete conversion o f
dithizone from its thione to its thiolate form. The peak at 466 nm is seen to shift 
to a lower wavelength of 443 nm.
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1 dithizone 
1
 ^ 215.9
í»BS 1.604
Figure 3.2 UV Spectrum of Dithizone
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Figure 3.5 UV Spectrum of Gold [I] Pith ¡Tonate
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It can therefore be concluded that the gold (I) must be interacting with the thiol 
or secondary tautomeric form in which the hydrogen of the sulphydryl group, as 
well as the hydrogen of the imide group is replaced by the metal (Figure 3.6).
C6H5
Au —  S Au
C«H5
Figure 3.6 Structure of Gold Dithizonate
3.2.2.4 Dithizooe HPLC Results
In the preliminary chromatography work, two peaks were detected by the on-line 
UV/vis detector at 450 nm (Figure 3.7B) The average retention times of the peaks 
were t^ =  3.6 minutes and tR =  4.6 minutes. The control solution (A) (prepared 
without disodium aurothiomalate) gave rise to only one eluting solute peak at t^ =
3.6 minutes (Figures 3.7A and 3.8). This peak can therefore be assigned to 
dithizone. As the peak eluting at t^ =  4.6 minutes increased in height with 
increasing disodium aurothiomalate concentrations, it can be concluded to be due 
to the formation of the gold (I) dithizonate complex (B). No peaks were detected 
on injecting a solution of disodium aurothiomalate alone.
2-mercaptosuccinic acid was added to the reaction mixtures of disodium 
aurothiomalate and dithizone to investigate its effect on the gold dithizonate 
complex formation. The resulting peak, attributable to the metal dithizonate 
complex, was seen to be notiecably diminished in the presence of the 2- 
mercaptosuccinic acid (Figure 3.7C). The presence of the acid within the reaction
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Dtz
B Au
Figure 3.7 A) Chromatogram of Control Sample where Dithizone is Extracted without 
the Presence of Disodium Aurothiomalate. B) Chromatogram of Disodium Aurothiomalate 
Extracted in the Presence of Excess Dithizone. C) Chromatogram of Disodium 
Aurothiomalate with Dithizone in the Presence of 2-Mercaptosuccinic Acid.
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( m i n )
Figure 3.8 Chromalograin of Gold 0) Dithizonate Formed in the Presence of 
Excess Dithizone.
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medium obviously suppressed the peak. This is attributable to the preferential 
interaction of the gold (I) in the disodium aurothiomalate with the 2-mercapto- 
succinic acid (thiomalate moiety) instead of the dithizone (Equation 3.1).
1/n [AuStmJn +  tmSH [AuStmJ- +  H+ (3.1)
It was noticed that the gold dithizonate peaks were neither stable nor 
reproducible. The complex was therefore unstable. The rate of formation of the 
extracted complex depends on the amount of gold present in the aqueous phase 
and the instability of the colour of the complex leads to errors in 
spectrophotometric analysis and detectionii2. Dithizone is very sensitive to 
oxidation and the oxidation product formed, carbodiazone S = C  (N=N Ar)2 (which 
is insoluble in alkali), can be present as an impurity. For these reasons further 
work to standardise the HPI-C gold dithizone method was abandoned. Dithizone 
was deemed to be an unsuitable reagent with which to complex gold (I) for 
purposes of detection and quantification by HPLC.
3.3 FORMATION OF GOLD CYANIDE
3.3.1 Materials
The potassium dicyanoaurate was obtained from Fluka (Gillingham, Dorset) and 
resorcinol, potassium cyanide and potassium dihydrogen phosphate were purchased 
from Sigma Chemical Company. The HPLC column was a Techsphere 50DS 
(octadecyl silyl) column (i.d 4.5 mm, length 250 mm) purchased from HPLC
Technology. All the other chemicals and instrumentation was as described in 
section 3.2.1.
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3.3.2 Standard Curve o f Potassium Dicyanide Obtained by Reacting 
Disodium Aurothiomalate with Potassium Cyanide
A reliable analytical method that can be used to detect low-molecular weight gold 
in biological fluids of rheumatoid arthritis patients undergoing gold therapy needs 
to be developed. For a successful HPLC method, a stable gold (I) complex that 
can be separated and absorbs well in the UV/vis region would be desirable. The 
formation of the complex potassium dicyanoaurate by addition of excess
potassium cyanide to the gold drug disodium aurothiomalate was investigated for 
this purpose.
A UV spectrum of standard commercial potassium dicyanoaurate (KAu(CN)2) was 
run to record the absorbance maxima for the purpose of setting the HPLC UV 
detector at the optimum wavelength (Figure 3.9). Water was used as the blank. It 
was seen that there are 5 absorbance maxima at 196.5 nm, 204.3 nm, 211.1 nm, 
229.9 nm and 239.2 nm. The maximum absorbance occured at 211 nm and so the 
HPLC UV detector was set at this wavelength.
Standard solutions of disodium aurothiomalate of concentrations 10.0, 25.0, 50.0,
100.0 and 200.0 x 10^ mol dm-3 were prepared, to each 1.0 mL aliquot an equal 
volume of 5.00 x mol dm-3 of KCN was added. The mixtures were left for 
40 minutes in a fume cupboard prior to injection on to the HPLC column. A 
control was set up by injecting separately a 1.00 x 10-^  mol dm*3 solution of 
disodium aurothiomalate, and then a 5.00 x 1(H mol dm-3 solution of KCN.
With lower concentrations of aurothiomalate no peaks were seen in the 
chromatograms, therefore the sensitivity had to be increased. However the 10 fold 
increase in sensitivity, from R = 0.1 to R =  0.01, coupled with the low UV
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Figure 3.9 UV Spectrum of 5.00 x 1(H mol dm-3 Potassium Dicyanoaurate (I).
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wavelength gave rise to a very noisy baseline. The HPLC column had to be 
washed through with deionised water for 4 days to allow the baseline to become 
steady at the higher sensitivity. The mobile phase used was a 0.15 mol dm-3 
potassium dihydrogen phosphate (pH 6.5) (KH2PO4). All the mobile phases used 
were degassed for 20 minutes prior to use. This was done mainly to prevent air 
bubbles forming within the column and also to expel oxygen as dissolved oxygen 
can lead to reaction and deterioration of the stationary phase as well as to the 
alteration of the sample components. The temperature of the column was kept as 
constant as possible at room temperature.
3 .3.3 Chromalogiaiii o f a  RA Blood Serum UltiafUtiale
Before finding an appropriate internal standard, a chromatogram of a rheumatoid 
arthritìs blood serum ultrafiltrate sample needed to be run in order to see where 
all the major peaks (components) would elute. This was necessary to make sure 
that the chosen internal standard would elute in a gap in the biological 
chromatogram and not be masked by any major biological components.
The blood serum samples were obtained from the Royal London Hospital Medical 
College from rheumatoid arthritis patients. The samples were kept ftozen at -34°C 
until they were ready for use. The serum was allowed to thaw out at room 
temperature and then 1.00 mL of it was pipetted into an ultrafltration device. The 
ultrafiltration device was a centrifree micropartiton system manufactured by 
Amicon (Stonehouse, Gloustershire). The sample was then centrifuged at 2000 g 
for 30 minutes. The micropartition device works on the principle that the 
biological sample is filtered through a anisotropic, hydrophilic ultrafiltration
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membrane by the pressure provided by centrifugation. The membrane has a 
molecular weight cut-off of 30,000 so that only molecules with a molecular weight 
lower than that are allowed to pass through and are collected as the ultrafiltrate. 
As macromolecular molecules, proteins are prevented from passing through the 
membrane, so the collected ultrafiltrate is free from protein-bound ligands and 
contains only lower molecular weight molecules.
The rheumatoid arthritis blood serum ultrafiltrate was injected onto the HPLC 
column using the usual operating conditions. A representative chromatogram of 
serum ultrafiltrate is shown in figure 3.10. It is seen that nearly all the 
components in the serum ultrafiltrate have eluted after 16 minutes. Therefore the 
internal standard used needs to elute after this.
3.3.3 Obtaining an Internal Standard
In HPLC it is very important to have an internal standard, as it allows for 
fluctuations in operating conditions from sample to sample. An internal standard 
must meet several criteria; it must be spectrophotometrically active at the 
wavelength at which the UV detector is set, it has to be completely resolved and 
not be overlapping or masked by any other peak, it should not be present in the 
sample and should not react or interfere with the sample.
Known concentrations of the internal standard are chromatographed and a plot of 
peak a r ^  against concentration was set up. On chromatographing the unknown 
sample a known concentration of the internal standard is added to it. Therefore 
any variation in the sample size, or any temperature or pressure changes are
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Figure 3.10 Reversed Phase HPLC Chromatogram of a Typical Blood Serum 
Ultrafiltrate Sample from a RA Patient. Mobile Phase 0.15 mol dm*3 KH-,P04 , Flow
Rate: 1.0 ml/min, Detector Wavelength: 211 nm. Response Factor, R: 0.05, Chart 
Speed: 0.5 cm/min.
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immediately apparent by comparing the peak areas of the internal standard from 
run to run. A correction factor can therefore be applied on determining the 
concentration of unknown in the sample. Therefore when a standard curve of the 
sample is produced, the correction factor is applied by plotting the area of the 
unknown sample peak (A J divided by the area of the internal standard peak (A,s) 
against concentration.
In this particular case, an internal standard was needed that eluted after the low- 
molecular weight components present in the biological fluid ultrafiltrate samples 
but that did not have too long a retention time. Various chemicals were tested for 
this purpose, some of which were not spectrophotometrically active at the desired 
wavelength of 211 nm. Caffeine and catechol were found to elute too soon and 
potassium ferrocyanide eluted with the solvent front at about t^ =  1.8 min. 
Quinol gave rise to a peak at t^ =  8.0 min which was not suitable since the 
compound of intrest, potassium aurocyanide eluted at the same retention time. The 
aromatic alddiyde vanillin was found to have too long a retention time, eluting 
well after all the other components present in the ultrafiltrate. Rhodamine was 
found to have a suitable retention time of tR =  18.0 min but it was deemed 
inappropriate for use as an internal standard as it reacts with gold. Finally the 
compound resorcinol (1,3-dihydroxybenzene), was injected and it gave rise to an 
eluting peak with an average retention time of tR =  16.0 minutes, appearing after 
nearly all the biological fluid ultrafiltrate components have eluted, therefore 
making it suitable for an internal standard (Figure 3.11).
OH
Q  I Figure 3 . 1 1  Resorcinol
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A stEndard CElibrstion curve for resorcinol was set up by injecting concentrations 
of 2.0, 4.0, 5.0, 6.0, 7.0, 8.0 and 10.0 x lO-^  mol dm*3 into the HPLC column. 
The mobile phase used was 0.15 mol dm-3 KH-,P04.
3.3.4 Standard Curve of Potassium Dicyanoaurate with Resorcinol as Internal 
Standard
A working baseline was attained with the higher sensitivity of R =0.01, therefore 
another potassium dicyanoaurate standard curve was constructed with lower 
concentrations more applicable to the level of “free" gold present in biological 
samples of RA patients undergoing chrysotherapy. Standard solutions of disodium 
aurothiomalate of concentrations 2.0, 4.0, 6.0, 8.0 and 10.0 x 10-6 mol dm*3 were 
prepared. 0.5 ml of potassium cyanide (0.5 x 10-  ^ mol dm-3) was respectively 
added to 0.5 ml of each aurothiomalate standard solution. The mixture was left for 
30 minutes to allow the formation of potassium dicyanoaurate to go to completion.
Resorcinol was then added to the mixture as an internal standard (final 
concentration 2.5 x 10-5 mol dm-3).
A standard curve of commercial potassium aurocyanide was also constructed with 
concentrations of 1.0 x 10-6 ^o l dm-3, 2.0 x 10-6 mol dm-3, 3.0 x 10-6 mol dm-3,
4.0 x 1(^6 mol dm-3 and 5.0 x 10-6 mol dm-3, with resorcinol (final concentration
2.5 x 10-5 mol dm-3) included as the internal standard. The two standard curves
obtained were very similar and the best straight line is drawn through them (Graph 
3.1).
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In the calibration graph below, the ratio of the HPLC peak area of potassium 
dicyanoaurate (A^) compared with the internal standard area (Ajs), was plotted against 
concentration. The potassium dicyanoaurate peak was either produced by the addition of 
excess KCN to given concentrations of disodium aurothiomalate (C>)» or by injection of 
conunercially obtained potassium dicyanoaurate (x). Both sets of results were plotted on 
the graph and one straight line was drawn (Beer's law assumed), as it is assumed that the 
concentration of disodium aurothiomalate is equivalent to the concentration of KAu(CN)2 
formed in excess KCN.
G iq ib  3 .1  Standard Calibration Graph for both Disodium Aurothiomalate and Potassium 
Dicyanoaurate.
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3.4 RESULTS AND DISCUSSION
A clear peak at an average retention time of tR = 8.0 minutes is seen (Figure 
3.12). No peaks were seen to elute at 211 nm on injecting either potassium 
cyanide or disodium aurothiomalate on their own. These controls prove that the 
presence o f the peak at t^ =  8.0 min is due to the formation of potassium 
dicyanoaurate on addition of excess cyanide to the gold drug disodium 
aurothiomalate. This was further verified by eluting a commercial solution of 
KAu(CN)2, which also exhibited a peak at tR =  8.0 min. Indeed, on addition of 
commercial KAu(CN)2 to the cyanide-aurothiomalate mixture the peak was seen to 
increase in size, retaining its symmetry. This is known as "spiking" and is a 
common chromatogn^hic tool for confirming suspected identity of an unknown 
compound and is very important method in qualitative HPLC analysis.
The linear complex ion [Au(CN)2]- is perhaps the most stable formed by gold (I), 
the stability constant has been estimated in aqueous solution as:
Au+ +  2CN- ±  [Au(CN)2]- K * \(P9
The metal-caibon bond strength in [Au(CN)2]- is high compared to other similar 
metal cyanides such as [Ag(CN)2J* and this is probably at least partially 
responsible for the overall stability constant for the formation of [Au(CN)2]’.
It is therefore expected that the dicyanoaurate ion should form on addition of 
excess cyanide to the aurothiomalate (Autm) as has been previously reported^ 
When there is an equal 1:1 ratio of gold (I) to cyanide, intermediates such as 
[tmAuCN]- form. On addition of excess cyanide the thiomalate is displaced.
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Figiire 3.12 HPLC Chromatogram of 1.00 x 10^ mol dm"  ^ Aurothiomalate Reacted with 
1.25 X 10^ mol dm‘3 KCN and 2.50 x lO"^  mol Resorcinol (Internal Standard). Mobile 
Phase: 0.15 mol dm-3 Potassium Dihydrogen, Flow Rate: 1 ml/min, Detector 
Wavelength: 211 nm, Chart Speed: 0.5 cm/min. Response Factor: R = 0.1.
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Autm +  HCN e -   ^ [AutmCN]- +  H-»- 
[tmAuCN]- + HCN ^   ^ [AuiCNOJ* +  tmH
The peaks assigned to [Au(CN)2]‘ i** chromatogram were not detected at 
lower aurothiomalate concentrations at the first working sensitivity of R = 0.1. 
Since the levels o f "free" gold generally encountered in blood plasma of patients 
undergoing treatment with disodium aurothiomalate is low, as it is approximately 
5% of the total circulating gold^i , a higher sensitivity needed to be achieved. The 
sensitivity was increased to R =  0.01 giving a noisy baseline but after 
equilibrating the column with water for a few days, a good working baseline was 
achieved. The standard curve for aurothiomalate was reconstructed at a lower and 
therefore more applicable concentration range. Sharp, symmetrical well resolved 
peaks were obtained down to a concentration of 1.0 x 10^ mol dm-3. An example 
of the chromatograms obtained is seen in Figures 3.12-3.15. The standard curve 
for commercial K[Au(CN)2] was reconstructed in the same concentration range. 
It can be seen that the slopes of the two curves are very similar. From this it can 
be concluded that virtually all the gold in the disodium aurothiomalate is being 
converted into the detectable potassium dicyanoaurate in the presence of excess 
cyanide. There is a very slightly greater response for commercial standard
K[Au(CN)2] Ihan for the K[Au(CN)2] formed from the disodium aurothiomalate at 
the same concentration.
To investígate how the formation of the K(Au(CN)J from action o f excess 
cyanide on aurothiomalate alters with time, UV spectra at 211 nm were repeatedly 
run at increasing time intervals. The results can be seen from Figures 3.16a)-h). 
The second derivative of the UV absorbance specra was displayed in order that the 
intensities of the peaks could be followed at the exact peak maxima. It can be seen
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Figure 3.13 HPLC Chromatogram of 2.00 x 10< mol dm-3 Aurothiomalate 
with 1.25 X l(H  mol dm-3 kCN and 2.50 x lO-’ mol Resorcinol amernal Standard). 
Mobile Phase: 0.15 mol dm-3 Potassium Dihydrogen, Flow Rate: I ml/min. Detector 
Wavelength. 211 nm. Chart Speed: 0.5 cm/min. Response Factor: R = 0.1.
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Figure 3.14 HPLC Chromatogram of 2.00 x 10^ mol dm-3 Potassium Dicyanoaurate 
and 2.50 x lO-^  mol Resorcinol (Internal Standard). MobUe Phase: 0.15 mol dm-3 
Potassium Dihydrogen, Flow Rate: 1 ml/min, Detector Wavelength: 211 nm, Chart 
Speed: 0.5 cm/min, Response Factor: R = 0.1.
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Figlire 3 .IS HPLC Chromatogram of 3.00 x 10^ mol dm*^  Potassium Dicyanoaurate 
and 2.50 x lO-^  mol Resorcinol antemal Standard). Mobile Phase: 0.15 mol dm-3 
Potassium Dihydrogen, Flow Rate: 1 ml/min, Detector Wavelength: 211 nm. Chart 
Speed: 0.5 cm/min. Response Factor: R = 0.1.
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Figure 3.16a-h UV Spectra Showing how the Action of Excess Cyanide (5.00 x 10^ 
mol dm-3) reacted with Aurothiomalate (1.0 x 10^ mol dm-3) Changes with Time, 
a) After 20 mins b) After 70 mins.
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that the absorbance at 211 nm due to the formation of K[Au(CN)2] increases in 
intensity with time. The greatest increase occurs between 0-120 minutes after the 
addition of excess potassium cyanide. Since it is impractical to wait 120 minutes 
after the addition of cyanide before chromatographing the solution, a compromise 
is made and the mixture is left to react for 40 minutes before introduction onto the 
HPLC column. As can be seen a high sensitivity is achieved with the detection 
limit for K[Au(CN)2] 1.0 x 10^ mol dm'^. This is of a value at and below 
that which can be expected to be found in patients being injected with gold 
therapeutic agents (1.5-4.0 x 10-  ^ mol dm-3).
3.5 CONCLUSION
For the purposes of detecting the low molecular weight "free" gold (I) present in 
rheumatoid arthritis patients undergoing chrysotherapy, the formation of the stable 
compound potassium dicyanoaurate, K[Au(CN)2], has been achieved by reacting 
the gold containing drug disodium aurothiomalate with excess potassium cyanide. 
The compound is formed almost instantaneously and is one of the most stable to 
be found in gold(I) chemistry. The peak for K[Au(CN)2] clearly separated by 
HPLC and detectable at 211 nm by an on-line UV detector. A good standard 
curve is achieved with resorcinol as the internal standard, down to low 
concentrations, suitable for quantification of the "free" gold (I) in relevant 
biological samples.
The high sensitivity achieved and the stability of the formed compound make this 
method suitable for quantifying low molecular gold in ultrafiltrate biological 
samples obtained from RA patients undergoing chrysotherapy.
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after the addition of cyanide before chromatographing the solution, a compromise 
is made and the mixture is left to react for 40 minutes before introduction onto the 
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be found in gold(I) chemistry. The peak for K[Au(CN)2] clearly separated by 
HPLC and detectable at 211 nm by an on-line UV detector. A good standard 
curve is achieved with resorcinol as the internal standard, down to low 
concentrations, suitable for quantification of the "free" gold (I) in relevant 
biological samples.
The high sensitivity achieved and the stability of the formed compound make this 
method suitable for quantifying low molecular gold in ultrafiltrate biological 
samples obtained from RA patients undergoing chrysotherapy.
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CHAPTER 4
DEVELOPMENT OF AN ANALYTICAL METHOD FOR THE 
DETECTION OF LOW MOLECULAR WEIGHT GOLD fl) 
PRESENT IN BIOLOGICAL FLUIDS OF RHEUMATOID 
ARTHRITIS PATIENTS UNDERGOING CHRYSOTHERAPY
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4.1 INTRODUCTION
As mentioned in the introduction, studies of the molecular pharmacology of gold 
drugs have established that both protein-bound and ultrafilterable (low-molecular 
weight) species of gold are found in blood plasma and synovial fluid following the 
parenteral administration of aurothiomalate38.39.ii4 xhg f^te of the gold between 
the time of administration and that of excretion is of primary importance in 
understanding the mechanism of gold (I) action in rheumatoid patients undergoing 
chrysotherapy. There is therefore a need to find a efficient, sensitive and selective 
analytical method for the study of gold (I) drugs in vivo.
A number o f analytical methods have been used to monitor gold levels, both 
protein bound and non-protein bound in human blood plasma, using disodium 
aurothiomalate pre-labelled with in and in vivo, using flame^*^ and
electrothermal ^  atomic absorption spectrometry, and neutron activation 
analysis! 1'^ . Ward et n/n* determined gold fractions by all three methods. Time 
consuming pre-treatment precluded all the analyses. Flame and electrothermal 
atomic absorption analysis was reported to give relatively low sensitivity, 
particularly in the measurement of the low-molecular weight gold (I) fractions. 
Flame atomic absorption requires large sample volumes and minimal dilution is 
required for a sensitive signal. Poor efficiency of the nebuliser-bumer system was 
noted. Electrothermal atomic absorption suffers from matrix interference. Kamel 
et alii^ determined blood serum gold levels in proteins separated by 
electrophoresis using carbon furnace atomic absorption spectrometry.
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Work done by Rayner et involved the separation and detection of both 
protein bound and low-molecular weight gold species by a technique which 
incorporated a combination of fast protein liquid chromatography and eluant 
analysis by flame atomic absorption spectroscopy. The system was supplemented 
by continous electronic absorption detection at 254 nm. Their results indicated that 
more than 50% of the gold is associated with a peak identified as serum albumin 
after a 5 minute incubation period and by 30 minutes more than 90% is found 
associated with the albumin. The FPLC method used in the Rayner analysis gave 
rise to broad peaks relative to analytical HPLC peaks. This in turn lessens the 
detection limits capable of being analysed.
The form in which a drug circulates invariably influences its biological effect and 
it has been shown that for many drugs the unbound fraction is of prime 
importancei20. with the administration of aurothiomalate, the relatively low levels 
of non-protein bound, low- molecular weight gold (I) present in plasma and 
synovial fluid are likely to play an inportant role in the attainment of an 
equilibrium of gold amongst the protein binding sites and hence be of vital 
importance in the understanding of the drug action itself. For this reason a rapid, 
highly sensitive and selective methodology needs to be developed to measure the 
low levels of non-protein bound gold in blood plasma and synovial fluid of 
rheumatoid arthritis patients undergoing gold (I) thiolate therapy. The HPLC 
method developed in Chapter 3 was employed to measure the low-molecular gold 
fraction o f the biological fluids after removal of protein-bound gold moieties by 
use of an ultrafiltration device. Atomic absorption spectrophotometry was used as 
a corroborative analytical method.
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4.2 MATERIALS AND METHODS
Disodium aurothiomalfltc was obtained from Rhone-Polenc (Dagenham, Essex). 
The potassium dicyanoaurate was obtained from Fluka (Gillingham, Dorset) and 
resorcinol, potassium dihydrogen phosphate were purchased from Sigma Chemical 
Company. All the chemicals used were of an analytical grade. Gold chloride for 
the AA standard work was of a Spectrosol grade and was obtained from BDH. 
Any other chemicals used were of the highest grade available.
4.2.1 Instnimentation
Chromatographic experiments were performed using apparatus as described in
3.2.1 and a column as described in 3.3.1.
For atomic absorption work a Varian SpectrAA 10/20 spectrophotometer 
autosampler was used in conjunction with a Varian GTA 96 graphite tube
atomiser. A gold hollow cathode lamp was utilised and unless stated otherwise was 
run at 8 mA.
Ultrafiltration of the samples was carried out using a CentrifreeTM Micropartition
System (product number 4104) purchased from Amicon Ltd (Stonehouse, 
Gloucestershire).
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4.2.2 Prqsaration of Biological Samples
1.0 mL of the biological samples were centrifuged at 3200 rpm for 25 minutes in 
a micropartition system. The micropartition system (Figure 4.1) is a disposable 
ultrafiltration device which prepares a protein free filtrate. The sample (1.0 mL) is 
placed in a sample reservoir at the end of which is an anisotropic, hydrophilic 
membrane. The membrane exhibits high permselectivity due to narrow pore size 
distribution. Under centrifugal force the protein component of the sample is unable 
to pass through the membrane. The filtrate containing the free ligands collects in 
the ultrafiltrate cup whilst the protein bound ligand and other macromolecules 
which are substantially larger than the membrane skin pores remain behind. The 
filtrate can then be analysed without further pretreatment. Over 99.9% of the 
serum protein can be removed this way.
4.2.3 Method
Relevant biological samples were provided by the Bone and Joint Research Unit 
at The Royal Ixindon Hospital Medical College. Samples were obtained from 
rheumatoid arthritis patients undergoing gold therapy, who had previously reached 
steady-state levels (cumulative doses of 10-50 mg of Myocrisin per week over a 6- 
12 week period of time^2i), piasma and synovial fluid was taken from patients at 
various times after a gold injection. The samples were taken between 1/2-24 
hours after a Myocrisin injection. After collection, the biological fluids were 
immediately frozen at -20®C to prevent further reaction of aurothiomalate with 
endogenous thiol groups.
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F igure 4.1 a) Diagram of the Ultrafiltration of Biological Fluids by the Micropartition 
System, b) Diagram of the Micropartition Component Parts.
116
The biological samples (blood serum and/or synovial fluid) were thawed out at 
room temperature from the freezer. It was presumed that no significant 
decomposition of the sample had occured whilst frozen. On thawing 1.0 inL of the 
biological sample was pipetted into a micropartition device which was then 
centrifuged at 3200rpm for 25 minutes. The resultant ultrafiltrate (about 80 fxL) 
was utilised for analytical HPLC and AA work.
4.2.4 HPLC Procedure
80 fiL of the resultant ultrafiltrate was pipetted into 20 /xL of 5.0 x 10-  ^ mol 
dm-3 potassium cyanide (final concentration 1.0 x 10*^  mol dm-^) and left to react 
for 30 minutes at room temperature. This mixture was then split into two equal 
aliquots. To one 50 /xL aliquot, 15 of water and 5 /xL of 3.5 x lO "^ mol dm*3 
resorcinol (final concentration 2.5 x 10-5 mol dm-3) was added. To the other 50 
/xL aliquot, 15 /xL of 1.0 x 10*5 mol dm*5 potassium dicyanoaurate (final 
concentration 23.08 x 10-^  „lol dm-3) and 5 /xL of 3.5 x 10-  ^ mol dm-3 resorcinol 
was added. Hence the second aliquot was ''spiked" in order to identify the 
dicyanoaurate peak in the biological sample.
The two samples were injected onto the HPLC column through a 50 fiL injection 
loop. The flow rate was 1 mL/min and the mobile phase was an aqueous solution 
of potassium dihydrogen phosphate (0.15 mol dm-3, pH 6.5). The UV detector 
was set at 211 nm, the A a^x for of the potassium dicyanoaurate (KAu(CN)2) (refer 
to Chapter 3). The chart speed was set at 1 cm/min. A standard was run prior to 
each analysis as a check and a fresh calibration curve was constructed every two 
weeks.
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The volume of synovial fluid in a normal joint is relatively small and in an 
arthritic joint the volume increases but the viscosity of the synovial fluid 
decreases. This small volume accompanied by pain experienced by the patient 
when having synovial Ouid withdrawn through a large needle, make it impossible 
and impractical to collect a large amount of sample. As only 1.0 mL of biological 
sample was collected from the patients, only about 80 fiL  of ultrafiltrate was 
yielded. This volume of ultrafiltrate did not allow for duplicate runs to be carried 
out on the same biological sample.
4.2.5 Atomic Absoiption
The program for the AA spectrophotometer was set up as follows:
Instrument Mode 
Calibration Mode 
Measurement Mode 
Lamp Position j
Lamp Current (mA) g
Band Pass (nm) i.o
Wavelength (nm) 242.8
Sample Introduction Sampler Automixing 
Time Constant o.05
Measurement Time (sec) 1.0
Replicates 2
Background Correction OFF
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The furnace parameters of the spectrophotometer were set up as below:
Step No. Temp ®C Time (sec) Gas Flow (L/min)
1 . 85 5.0 3.0
2 . 95 40.0 3.0
3. 120 10.0 3.0
4. 500 5.0 3.0
5. 500 5.0 3.0
6. 500 2.0 0.0
7. 2600 1.2 0.0
8. 2600 2.0 0.0
9. 2600 2.0 3.0
The gas type was argon.
Gold standards were prepared with Spectrosol grade gold chloride (1.0 mL = 1.0 
mg Au =  5.08 mmol/L) and the standard curve was set up. Ultrafiltrate samples 
were then analysed for gold concentration.
The samples were dried for the first 55 seconds of the analysis at iip to 120®C 
and were then ashed for 12 seconds at 500®C, and atomised at 2600®C.
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4.3 RESULTS AND DISCUSSION
A number of difficulties were experienced in setting up a viable quantitative 
analysis of the biological samples by HPLC. Baseline drift was experienced with 
the high sensitivity required and the column had to be conditioned by flushing 
through with HPLC grade water overnight. Normal problems associated with 
HPLC such as the presence of air bubbles within the column and pressure 
fluctuations were exacerbated by the small volume of samples making reanalysis of 
affected samples unfeasable. Injecting numerous biological samples over an 
extended period of time onto the HPLC column, caused the column to become 
contaminated with a variety of biological fluid constituents. This would be 
indicated by the splitting of peaks. To alleviate this problem the contaminated 
stationary phase at the top of the column was removed and the column repacked. 
Repacking would become more frequent as the age of the column increased. After 
about every 6 months a new column was purchased.
Figure 4.2 shows a typical chromatogram of an "unspiked" synovial fluid filtrate 
from a RA patient undergoing chrysotherapy that has been reacted with excess 
potassium cyanide. It is expected that any "free" unreacted gold present in the 
biological ultrafiltrate would react with the excess cyanide to form the stable 
compound potassium dicyanoaurate (KAu(CN)2)*®^ . From preliminary standard 
work (Chapter 3) it has been shown that KAu(CN)2 ^ average retention time 
(Ir) o f 8.0 minutes. Peak A seemed likely to be due to KAu(CN)2. I" order to 
confirm this the sample was spiked with a known amount of a dicyanoaurate 
standard. The chromatogram of the spiked sample is shown in Figure 4.3. As the 
only change noted was the increase in peak height this indicates that peak A is due 
to the formation of the dicyanoaurate complex in the presence of excess cyanide.
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Figure 4.2 HPLC Chromaogram of RA Chrysotherapy Synovial Fluid Ultrafiltrate 
(Sample AK31/1) with Excess Potassium Cyanide (1.00 x 10^ mol dm-3) and Internal 
Sttndard Resorcinol (2.5 x 10-5 „„I dm-3). Mobile Phase:0.I5 mol dm-3 Potassium 
Dihydrogen Phosphate (pH 6.5), Flow Rate: I inl/min. UV Detector Wavelength: 211 
nm. Sensitivity Response Factor, R =  o .O l, Chart Speed: 0.5 cm/min. Peak A = 
KAu(CN)j (tg = 10.6 min). Peak I = Internal Standaid (Resorcinol).
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R gure 4.3 HPLC Chromatogram of RA Chrysotherapy Synovial Fluid Ultrafiltrate 
(Sample AK3I/1) with Excess Potassium Cyanide (1.00 x 1(H mol dm-3) and Internal 
Standard Resorcinol (2.5 x 10-5 mol dm-3) "Spiked" with 2.5 x 10-5 mol dm-3 Potassium 
Dicyanoaurate Standard (KAu(CN>2). Mobile Phase:0.15 mol dm-3 Potassium Dihydrogen 
Phosphate (pH 6.5), Flow Rate: 1 ml/min, UV Detector Wavelength: 211 nm. Sensitivity 
Response Factor, R = 0.01, Chart Speed: 0.5 cm/min. Peak A = "Spiked" KAu(CN>2 
(tR = 10.6 min). Peak I = Internal Standard (Resorcinol).
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To further confirm this assignment the relative retention, a , of peak A, compared 
to the internal standard (resorcinol) was calculated for both the chromatograms.
Of, Relative Retention = Retention Time of Compound of Interest
Retention Time of Internal Standard
Peak A or. Rdative Retention
Unspiked A 2.04
Spiked A 2.04
Table 4.1 Relative retentions of A, KAu(CN)2
It can therefore be concluded that peak A in fig. 4.3 is attributable to the 
presence of dicyanoaurate in synovial fluid ultrafiltrate which is formed in the 
presence of low-molecular weight "free" gold with excess cyanide. A further 15 
ultrafiltrate samples were analysed by HPLC giving similar results. The average 
relative retention was 1.99 with a standard deviation of 0.21.
4.3.1 Quantitative Analysis
Quantitative analysts of the samples was achieved by calculating the area of 
KAu(CN)2 peak relative to the area of the internal standard peak. A standard 
catibration graph was prepared as detailed in chapter 3 and the concentration of 
low molecular weight gold in the biological sample was calculated after taking into 
account actual volume of ultrafiltrate over total injection volume.
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Table 4.2 Table shows Concentration of Low Molecular Gold present in 
Synovial Fluid of a RA patient Undergoing Chrysotherapy as Calculated 
from Chromatograms in Figs. 4.2 and 4.3.
o ther synovial Huid samples were analysed and the results are shown in Table 
4.3. It can be seen that the concentration of "free" gold in the synovial fluid 
samples is in the range of 1.70-3.01 x 10« mol dm-3. The average concentration 
was found to be 2.48 x 10« mol dm-3 .
Table 4.3 Concentration of Low Molecular Weight Gold in Synovial Fluid Samples 
from RA Patients Undergoing Chrysotherapy as Calculated from HPLC Chromatograms 
by Standard Additions Method. The Standard Deviation is 0.57 and the Mean 
Concentration is 2.48 x 1(H mol dm-3.
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4.3.2 Atomic Absorption Results
To verify the quantitative results obtained by HPLC analysis, RA synovial fluid 
samples were analysed by atomic absorption spectroscopy. After the setting up of 
a standard curve, synovial ultrafiltrate was analysed and the results are shown in 
Table 4.4.
Sample Cone (ppb) Mean Abs
Blank 0.00 0.007
Standard 1 4.00 0.590
Standard 2 8.00 0.116
Standard 3 12.00 0.171
Standard 4 16.00 0.220
Standard 5 20.00 0.256
Sample 1 14.46 0.202
Sample 2 13.06 0.184
Table 4.4 The absorbance of standards and of the synovial fluid ultrafiltrates as 
measured by atomic absorption spectroscopy. Sample 1 and sample 2 are labelled 
LH 29/1 and PG 19/2 respectively.
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From Table 4.4 the concentration of gold present in the ultrafiltrates was 
calculated in mol dm*  ^ taking into account the dilution of the original sample. The 
results are shown in Table 4.5.
Sample CoocentratioD /lO^ mol dnr^
Sample 1 
Sample 2
2.20
1.99
Table 4.5 showing the concentration of low molecular weight gold in representitive 
synovial fluid samples.
Further synovial ultrafiltrate was analysed by AA and the results are seen in 
Table 4.6. The average concentration is 2.16 x 10^ mol dm*3 .
Sample CoDoentiaiioa o f *ñee* Gold 
/IQ ^ mol dm-3
LH29/1 2.20
PG19/2 1.99
PG23/1/90 2.91
PG5/3/91 1.91
LH22/8 1.77
Table 4.6 Concentration of Low Molecular Weight Gold in Synovial Fluid of Patients 
Undergoing Gold Therapy as Calculated By Atomic Absorption Spectrometry. The 
Standard Deviation is 0.45 and the Mean Gold Value is 2.16 x 10^  mol dm-3.
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From the concentrations calculated by both HPLC and AA it can be seen that the 
concentration of free unbound gold in synovial fluid is in the region of 2.0  x 10« 
mol dm-5, which correlates well with previously <12,38 .
4.3.3 Analysis o f Plasma
Blood plasma ultrafiltrate was also analysed for low molecular weight gold
content by both HPLC and AA analysis. The HPLC results are seen in Table 4.7 .
Samples were taken both before and after a weekly 50 mg aurothiomalate 
injection.
Sample
Pre/Post Au Injectioa
Coocentratioo o f ■ftee" Gold 
/lO® mcd dnr^
Pte 50 mg (FH12/3) 4.62
Pre 50 mg (DB6/5) 5.11
Post 50 mg (1/2 Hr) (FH12/3) 11.90
Post 50 mg (1/2 Hr) (DB6/5) 12.80
Post 50 mg (1 Hr) (FH12/3) 7.30
TiWe 4.7 Concentration of Low Molecular Weight Gold in Blood Plasma of Patients 
Undergoing Chrysotherapy as Calculated by HPLC with Standard Additions Method 
n .e  Standard Deviation for Pre Injection is 0.35 and Post Injection is 2.95.
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Pre injection readings show an average concentration of 4.87 x lO-* mol dm-3 
Comparing the level of low molecular weight gold found in the synovia] fluid 
samples, with the levels found in the plasma by HPLC analysis gives a ratio of
1.2 respectively. This result ties in with previous results'”  that qoute the synovia] 
fluid to plasma "free” gold ratio is 1 : 1 .8.
It is seen that post injection plasma samples (1/2 hour post injection) show quite 
a large increase in "free” (non-protein bound) gold concentration as expected (up 
to a 7.69 X 10« mol dm-3 increase). There is a 2.5 fold increase in the “free" 
gold level in plasma samples taken 30 minutes post injection. These results concur 
with those obtained by Danpure et aP», who reported that the concentration of 
unbound gold increases 2-5 fold after an aurothiomalate injection, reaching a 
maximum level 10-30 minutes post injection. The uptake of the aurothiomalate by 
albumin in human blood plasma is slow".i2, but eventually most o f the gold 
injected becomes albumin bound (80-90%), and the level of low molecular weight 
"free" gold decreases accordingly. Rayner e, aP^ observed that after a reaction 
time of 55 mmutes nearly all the gold was albumin bound (Figure 4 .4). Other 
workers3> found that the binding plateau for albumin was not reached for 5 
hours. The post injection plasma sample taken 1 hour after administration of 
aurothiomalate, shows the non-protein bound gold level falling to 7.30 x 10«  mol
dm-3 as the gold becomes predominantely albumin bound and a steady state is 
eventually attained again.
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Figure 4.4 Plots of the decrease in concentration of non-protein bound, "free" gold 
with time (•) and the increase in the concentration of albumin bound gold with time (o) 
after administration of disodium aurothiomalate (final concentration 4.0 x mol dm-3) 
to human plasma as shown by Rayner et aP^.
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Table 4.8 shows the results of plasma analysis by atomic absorption spectroscopy.
Sample Ultrafiltrate [Au] Total [Au]
/ 1(H  mol dnr3 /lO^ mol dm-3
Pre 50 mg Au injection 3.28 3.44
Post 50 mg Au injection (1 Hr) 3.86 4.24
Table 4.8 Concentration of Gold in Ultrafiltrate and Whole Plasma Sample as Analysed 
by AA. Standard deviation is 0.43.
Both the ultrafiltrate (unbound gold content) and the whole plasma sample (total 
gold content) were analysed by AA. The pre injection unbound gold content 
plasma sample from this patient is somewhat lower than the plasma sample analys­
ed by HPLC. The level of unbound gold in the post injection plasma ultrafiltrate 
sample taken 1 hour after the aurothiomalate injection (3.86 x 10^  mol dm*3) is 
only slightly higher than the pre injection level (3.28 x 10^ mol dm-3). This is 
due to the fact that 1 hour after the aurothiomalate injection the relatively slow 
uptake of aurothiomalate by albumin had taken place and the gold levels had 
almost reached a steady state again. This would account for the relatively close 
values obtained for both the pre and post injection ultrafiltrate samples.
130
The values obtained by AA for total gold content of plasma (Table 4.8) are very 
low indeed and are deemed unreliable as no clean-up or digestion of the biological 
sample was made prior to aspiration. This leads to matrix interference from the 
large protein molecules present and also sample introduction problems. To attempt 
to evaluate plasma total gold content the sample has to be treated and digested. 
This investigation centered on the concentrations of only the unbound low 
molecular weight gold found in biological fluids of RA patients undergoing 
chrysotherapy, so analysis of total gold content was not further pursued.
Table 4.9 shows the concentrations of unbound gold from plasma ultrafiltrates as 
analysed by atomic absorption. The levels are lower than those recorded on plasma 
analysis by HPLC.
Sample Concentration o f "free" Gold 
/lO ^ mol dm-3
PG15/1 3.24
PG23/1/90 3.33
PG5/2/91 2.91
PG5/3/91 1.91
LH26/2 3.54
Table 4.9 Concentration of Low Molecular Weight Gold in Blood Plasma of RA
Patients Undergoing Gold Treatment as Analysed by AA. The Standard deviation is 0.64 
and the mean Gold Value is 2.99 x 1(H mol dm-3.
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4.4 CONCLUSION
The concentration of unbound, low molecular weight gold in blood plasma is 
thought to make up approximately 5% of the total gold content. However, 
previous investigations into the levels of "free" gold found in rheumatoid arthritis 
patients undergoing gold therapy have been contradictory. Campion et al^-- have 
reported levels of 8-10% unbound gold, 2-4 weeks after 50 mg aurothiomalate 
injections whilst Kamel et failed to detect any in some samples.
Although the concentration of low molecular gold is small (relative to the total 
gold content) and appears to vary widely, it is thought to play an important role 
in the attainment of equilibrium, transport processes and excretion of gold. The 
rate of interaction however, between aurothiomalate and albumin in vivo might be 
expected to play a key role in the size and the duration of peaks attributable to the 
unbound gold.
In this study it has been found that the level of unbound gold in synovial fluid is 
in the region of 2.0 x 10-  ^ mol dm*3. These results are consistent when analysed 
by both HPLC and atomic absorption spectroscopy. The plasma studies analysed 
by HPLC show that unbound gold is present in plasma in roughly double the 
quantity (4.0 x 10^ mol dm-3) to that found in synovial fluid, which tallies with 
the results obtained by other workers'^. The concentration of unbound gold rises 
by a factor of about 2.5 times after a 50 mg aurothiomalate injection as expected. 
The plasma results analysed by atomic absorption are found to be lower than those 
analysed by HPLC. However more samples need to be analysed by both methods 
to ascertain if this is a trend. In this study HPLC was used as the primary 
analytical method for non-protein bound gold analysis in biological fluids and
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atomic absorption spectroscopy analysis was utilised for corroboration. The A A 
results for synovial fluid corroborated well with those obtained by HPLC, but 
discrepencies were observed with the analysis of the plasma samples. AA analysis 
of the biological fluids suffered due to matrix effects and sample introduction 
problems and further pre-treatment and digestion of the samples is needed before 
analysis. However, the HPLC analysis provided a relatively quick analytical 
method for free" gold analysis in vivo with very little need for pre-treatment of 
the samples. In addition the HPLC is a relatively affordable piece of equipment 
commonly found in laboratories and as such this method might be developed for 
routine medical analysis.
The distribution of gold in biological fluids has been studied in 
Previous work on low molecular weight gold in human plasma has been analysed 
by neutron activation analysis, with fractionation of plasma by gel exclusion 
chromatography prior to analysis. This pre-requisite is very time consuming and 
gives a poor recovery of gold from the column. A less time consuming analytical 
method which could be used efficiently in a averagely equiped medical laboratory 
would therefore be of value. After overcoming initial problems, in this study 
HPLC was succssesfully used as a sensitive and selective analytical tool for low 
molecular weight analysis of gold in rheumatoid arthritis patients undergoing gold 
therapy.
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CHAPTER 5
INVESTIGATION OF THE MOLECULAR NATURE OF 
IMPLANT-DERIVED TITANIUM (III) AND TITANIUM OV) 
IONS IN TISSUE AND SYNOVIAL FLUID ADJACENT TO 
TITANIUM-ALLOY HIP PROSTHESES
134
5.1 INTRODUCTION
Titanium alloy implants have been extensively used in hip replacement surgery 
because of their biocompatibility, due to the presence of an inert titanium oxide 
layer on the implant surface^23,i24 However, the inertness of titanium in the 
biological environment has to be reviewed as on revision surgery for failed hip 
implants, dark staining of the tissue adjacent to the titanium prostheses has been 
observed in a number of cases.
S.1.1 Black Staining
The presence of a blue-black discolouration, due to titanium metal ions, has been 
reported to be present in tissue adjacent to the titanium alloy prostheses125-136, 
This unpredictable and occasional clinical finding of darkly stained soft tissues 
around the implant has given rise to the term '*metallosis"‘29.i3o.i35, xhis can be 
defined as aseptic fibrosis, local necrosis or loosening of a device secondary to 
metallic corrosion and release of wear debris. Numerous workers have described 
this clinical observation, with no clear explanation or predictable occurence.
Witt and Swann^27 reported 13 total hip replacements (17.3 %) needing revision 
surgery because of loosening, after an average of 2 years after implantation. They 
noted that soft tissues around the prostheses were darkly coloured and that a 
proliferative membrane had infiltrated the cement and bone interface. Agins et 
0/126 also noted this phenomenon and reported histiocytic and plasma cell reaction 
in the pseudocapsular tissue with the utilisation of Ti-6A1-4V (titanium-6 % 
aluminium-4 % vanadium) prostheses and ultra high weight polyethylene. A
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number of researchers examined the dark tissue histiologically, metallurgically and 
clinically. Goodman et studied the histological reaction to titanium alloy in 
rabbit tibia, whilst Rae^^s investigated the biological response to titanium and its 
alloy T1-6A1-4V, by exposing primary cultures of human synovial fibroplasts and 
mouse peritoneal macrophages to them. Microscopically the cells appeared 
unaffected but a small release of lactate dehydrogenase (LDH) was noted, 
indicating some cell damage. The mechanism by which titanium and its alloy 
cause the release of LDH is unclear. There are 2 possibilities; i)the effects may be 
due to the action of the soluble metal or ii) to the particles themselves.
Witt and Swani27 also reported that, on microscopic examination, the dark tissue 
was composed of fibroblastic tissue with extracellular dark fragments, also present 
within the histiocytes and foreign body giant cells. Microbiologically they found 
the culture negative. Black»29 stated that all metals, with the exception of maybe 
titanium and Ti-6A1-4V, are biologically active. Whilst these materials he deemed 
as being biocompatible in block form, he speculated that when present in 
particulate form, they induced a macrophage response by causing affected cells to 
release lysosomal enzymes, collagenase and interleukin, and prostglandins. Agins 
et found the cytoplasm of a few synovial cells and most of the histiocytes 
contained a number of black, opaque, irregular particles with an approximate 
diameter of 1-2 fim. They also carried out atomic absorption analysis on the 
stained tissue and found that the average concentrations of titanium to be * 1,000 
/ig/g, of aluminium - 100 /xg/g and of vanadium - 70 /xg/g. For all the metals the 
expected concentration was taken to be 0 ^g/g. The ratio of the 3 metals in the 
soft tissue,was found to be similar to the ratio of them within the prostheses. 
Other workersi28.i38 however, reported that the two ratios do not correlate. 
Indeed, Lalor et a/i28, found a complete absence of aluminium or vanadium 
within the affected tissues. This may be due to the fact that the 3 metals are 
handled differently in vivo and have differing solubilities. Animal studies^^^ have
136
shown that vanadium is very soluble and passes through the kidneys very quickly, 
whilst titanium is insoluble and remains in the tissues. Aluminium is more soluble 
than titanium and may be transported away from the implant site. The presence of 
titanium was also confirmed by energy-dispersive spectroscopy, where the affected 
tissue samples gave the characteristic titanium double peak at 15 kV*28.i40 
Meachim and Williamsi^i estimated titanium concentration by neutron activation 
analysis. They concluded that there was no correlation between titanium 
concentration and the time the implant had been in the body.
5.1.2 Oxide Needle Model
Solar et tried to explain the dark tissue phenomenon found adjacent to failed 
titanium alloy hip replacements by proposing a model for the surface corrosion 
and wear of the alloy. The model proposes that the titanium alloy achieves a 
microscopically rough surface due to the mechanical polishing at the manufacture 
of the implants. The oxide that forms on the surface, is composed of oxide 
needles at the surface irregularities and of a smooth planar oxide (Figure 5.1).
Figure S.l: Oxide needle model
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The oxide needles can be broken off by friction or can dissolve In vivo. This 
could account for the varying presence of titanium sometimes found in soft 
tissues. Mindell and Pollack'« describe similar titanium oxide needles in their
study of titanium thin film oxidation (they observed needles approximately 500 A 
long and with diameters of 75-200 A).
Overall titanium is still considered to be the most biocompatible metal for implant 
manufacture. Major histological responses in the tissue have been noted consistent 
with either allergy or chronic inflammation. In the failed hip prostheses, copious
metallic staining may form, which may be irritating to the adjacent tissues 
prompting immunological responses.
5 .1 .3  Titanium Gels
The sensitivity to titanium as described by U lo r et indicates that there is a 
deleterious proliferation of Ti (III)/Ti (IV) species present in tissue adjacent to the 
implant and in the synovial fluid and the synovium. To date little work has been 
carried out to determine the exact chemical nature of the titanium present. The in 
vivo corrosion of titanium in all likelihood involves a complex series of 
interdependant dissolution, acid-base and chelation reactions.
To further complicate the bioinorganic chemistry of titanium, Tengvall ei a / '44-i46 
have reported the presence of a clear yellowish green gel, when metallic titanium 
is in the presence of hydrogen peroxide (H.O^) in vitro. They have suggested that 
this gel is also generated in vivo from the reaction of the implant titanium metal 
with the HjOj. which is formed at the surgery site due to a respiratory burst of
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phagcx^ytosing cells, or an inflammatory response caused by the surgical trauma at 
the time of implantation. This gel contains superoxide radicals coordinated to 
titanium (IV) and appears to be composed of four different Ti (IV) species; 
Ti(IV)02 (OH%, Ti(IV)02* (OH-)x, Ti(IV)(OH )4, Ti(IV)02.nH20.
The superoxotitanium (IV) component, Ti(IV)02 * (OH )^ has a redox potential, 
Eq >  0.77 V, possibly as high as 1.7 V at pH 4 demonstrating its powerful 
oxidising properties. The gel readily oxidises superoxide to molecular oxygen,
reduced glutathione, probably to its corresponding glutathiol, and Fe(II) to 
Fe(III)28.
Sensitivity to titanium metal may be brought about by the release of the redox- 
active titanium (III) species from the prostheses, as this metal ion promotes the 
generation of the highly reacüve hydroxyl radical ( OH) from the hydrogen
peroxide (H2O2) produced at the implant site by the phagocytic cells as a result of 
the surgical trauma (equation 5 . 1).
Ti (III) -I- H2O2 -> Ti (IV) -1- OH + o n ­ es. 1)
The peroxidation of the membrane polyunsaturated fatty acids by the hydroxyl 
radical, leads to cell and tissue damage and this highly reactive radical has the
ability to modify the structure of the implant-localised proteins, so inducing 
immunological responses.
As the chemical spéciation of metal ions in vivo is important, the precise chemical 
nature of titanium (III) and titanium (IV) complexes within biological matrices 
(implant-localised tissue and knee-joint synovial fluid) have been studied in the 
foUowing work by FTIR and high field proton NMR spectroscopy. Tissue samples 
obtained from joints containing titanium alloy implants, were seen to contain a
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localised blue-black deposit which appears to consist of a polynuclear Ti (III) 
oxo/hydroxo complex. The production of this species was simulated in vitro, by 
the use of synthetic routes which involved its precipitation, from aqueous Ti (III) 
solution with biologically-relevant bases. FTIR spectra of the synthesised 
complexes and of dried titanium-containing tissue were run. The molecular nature 
of non-protein bound, implant derived, titanium (IV) in knee joint synovial fluid, 
was assesed by addition of increasing concentrations of Ti (IV) to the rheumatoid 
synovial fluid and following the reactions by high field proton, Hahn spin-echo 
NMR.
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5.2 MATERIALS AND METHODS
5.2.1 Reagents
Titanium potassium oxalate (dipotassium titanium (IV) oxyoxalate K2Ti0 (C204)2) 
was purchased from Hopkin and Williams Ltd. Zinc powder, titanium (IV) 
oxysulphate dihydrate (Ti0 S042H20), titanium (IV) sulphate solution (15% w/v 
1 1 (804)2), titanium (III) trichloride (TiClj), sodium hydroxide (NaOH), sodium 
carbonate (NajCOj), potassium dihydrogen phosphate (KH2PO4), disodium 
hydrogen phosphate (Na2HP04) and calcium chloride (CaCl2) were all of the 
highest grade, analytical if possible and were purchased from Aldrich. Analar 
trisodium citrate was obtained from Sigma Chemicals.
5 .2 .2  Methods
5.2.2.1 Reductkn o f Titaiiium (IV) Complexes and Chemical Modification of 
Reduction Products with Endogenous Anionic Ligands
5.2.2.1.1 Preparation o f a Dark-blue Multinuclear Titanium (III) Oxo/Hydioxo 
Complex with Titanium (IV) Oxysulphate
a) Precipilation with Sodium Hydroxide
0.75g of zinc powder was added to 5 .0  cm3 „ f  0.75 mol dm-3 ütanium (IV) 
oxysulphate (TiCHSO«)), which contained 23 % w/v sulphuric acid (HjSO«). This 
reaction mixture was left for 30 minutes at ambient temperature. During this time
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hydrogen gas evolved continuously and a deep violet colour developed in the 
solution. At the end of this period the colour was stable and no further gas 
evolved. The reaction was assumed to be complete. The final pH of the solution 
was found to be 5. A 1.0 mL sample of the dark violet solution was taken and 
mixed with sodium hydroxide solution (0.10 mol dm-3, 10.0 mL). A dark blue 
coloured precipitate formed. This was filtered, washed three times in degassed, 
distilled water and dried under vacuum. It was noted that the dark blue precipitate 
had a multicoloured "metallic" sheen on its surface. Fourier transform infra-red 
(FTIR) spectroscopy was employed to obtain the spectrum of the precipitate in the 
range 400-4000 cm L This spectrum showed a series of diffuse absorption bands 
found at 1143, 1048 and 990 cm*i, with a less well defined "shoulder" at 1213 
cm-* (Figure 5.2). These bands are characteristic of Ti (Ill)-sulphato complexes 
(mono- or bidentate co-ordination of sulphate), which can be presumed to be 
associated with polynuclear Ti (III) oxo/hydroxo complexes. The lower region of 
the FTIR spectrum displayed sharp absorption bands at 637 and 617 cm**. 
Exposure of the blue solid to atmospheric oxygen (> 7 2  hr) resulted in loss of 
colour. This was assumed to be due to the slow rate of transformation of Ti (III) 
to Ti (IV).
b) Measurement o f the Titanium Coocentratkn o f the Precipitate 
A standard curve was constructed by using varying concentrations of Ti (IV) 
oxysulphate (TiOS04 2H2O). Ti (IV) oxysulphate solutions of concentrations 0.50 
mmol dm-3, 0.75 mmol dm-3, 1.50 mmol dm*3, 2.50 mmol dm-3 and 3.00 mmol 
dm-3 were made up in 20.0 cm^ of 1 :1  1.80 mol dm-3 hydrochloric acid and 0.14 
mol dm-3 hydrogen peroxide. The solutions were left to stand for 2 hr and became 
orange in colour, with the colour intensity increasing with increasing 
concentration. UV spectra of the solutions were then run at 200-600 nm (speed 
125 nm/min).
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Figure 5.2 FTIR Spectnim of Blue Titanium OH) Oxo/Hydroxo Complex Prepared with 
Titanium (IV) Oxysulshate and Sodium Hydroxide.
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5.0 mg of the precipitate was treated similarly to the Ti (IV) standard solution. 
The solution was also left for 2 hr before an UV absorbance spectrum was taken 
at 200-600 nm. A graph was plotted from the standards of absorbance at Atn&x
(413 nm) versus concentration. A straight line graph was obtained which obeyed 
the Beer Lambert law, where A = eel (e =  extinction coefficient, c = 
concentration and 1 =  cell path length). Using this graph and knowing the 
absorbance at A„„  ^ obtained by the prepared precipitate, its concentration and 
hence its titanium content was calculated. The solid was found to have 56 % 
titanium.
c) Preci{ntatk)o with Sodium Carbonate
The dark violet coloured Ti (III) solution was prepared as in a), by the reduction 
of titanium aV ) oxysulphate (Ti(IV)OS04) with the Zn/HCl system. The solution 
was left for 30 min and then 1.0 mL of it was taken and to it was added 10.0 mL 
of 0.10 mol dm-3 sodium carbonate solution (NajCOj). A dark blue precipitate 
was formed which was filtered, washed 3 times in deaerated water and dried in 
vacuum in a desiccator. A FTIR spectrum of the sample was run (Figure 5.3) 
which showed absorption bands at 1112 cm** and 993 cm**, suggesting that the Ti 
a il)  sulphate species are associated with the product prior to its loss of colour 
(oxygen dependant). As with the -OH precipitated complex, the 850-400 cm * 
r^ io n  of the spectrum showed sharp Ti (III)-O stretches at 637 and 617 cm**, 
ecm cntal CHN analysis gave 0.20 % carbon and 1.65 % hydrogen. The 
occurence of carbon can be accounted for by the presence of the carbonate anion, 
which could be co-ordinated to the titanium or may just be present as a non co­
ordinated impurity due to excess sodium carbonate (NajCOj), exisited as a co- 
precipitate or possibly adsorbed on the surface of the precipitate. On prolonged 
exposure to air (>  72 hr) the dark blue precipitate lost its colour and became 
white as the Ti (III) was oxidised by O2 to Ti (IV).
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sFigure 5.3 FTIR Spectrum of Blue Titanium OH) Oxo/Hydroxo Complex Prepared 
with Titanium aV) Oxysulphate and Sodium Carbonate.
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d) Precipitatioo with Inorganic Phosphate
To 1.0 mL of violet coloured Ti (III) solution, obtained as in a) and b), 10.0 mL 
of an aqueous solution of phosphate buffer, pH 7.41 (8.70 x 10-3 mol.dm-3 of 
KHj PO4 , 3.04 X 10-2 mol dm-3 Na2 HPO4) was added^^^ , ^  pale blue 
precipitate was obtained, which was filtered, washed 3 times with distilled, 
degassed water and left to dry under vacuum in a desiccator. The precipitate 
rapidly lost colour and was converted to a white Ti(IV) containing solid on 
exposure to air. A FTIR spectrum of the autoxidised white solid was run and a 
strong absorption band at 1038 cm*i was seen which confirmed the presence of 
phosphate (Figure 5.4). The lower region of the spectrum (850-400 cm-i ) showed 
a number of overlapping bands including ones at 730, 607, and 500 cm-i , which 
were different from the bands obtained with the solid precipitated by sodium 
carbonate or sodium hydroxide. Elemental CHN analysis gave 0.00 % C and 
1.65 % H.
S.2.2.1.2. Prepaiatkn of a  Dark Blue Coloured T i (m) Precipitate Using 
Utanium  (IV) Potassium Oxalate (oxyoxalate)
a) Precipitatioo with Sodium Carbonate
To 10.0 mL of 0.10 mol dm-3 titanium (IV) potassium oxalate (K2Ti*vo(C204)2) 
1.5g of zinc powder was added, followed by 3.0 mL of 2.00 mol dm-3 
hydrochloric acid. The liquid changed from a clear to an orange-brown colour as 
the Ti (IV) was reduced to Ti (III) (presumably forming mono- or/and bis oxalato 
Ti (in) complexes). Gas, presumed to be hydrogen was seen to evolve. The 
reaction mixture was left at ambient temperature for 30 minutes until the zinc 
powder settled. 3.0 mL of this reduced solution was placed in a test tube and
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Figure 5.4 FTIR Spectrum of Blue Titanium aH) Oxo/Hydroxo Complex Prepared with 
Titanium aV) Oxysulphate and Phosphate Buffer pH 7.4.
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treated with 10.0 mL of 0.10 mol dm*  ^ sodium carbonate solution. A dark blue 
precipitate was formed, suspended in a now clear solution. The solid was filtered, 
washed with plenty of degassed water and dried under vacuum. Elemental CHN 
analysis gave results of 6.12 % C and 1.61 % H.
b) Predpitalioo with Sodium Hydroxide
The reduced titanium (III) orange-brown solution was prepared as previously 
described in a), and 10.0 mL of 0.10 mol dm*  ^ sodium hydroxide was added to
3.0 mL of the Ti (lU) solution to yield a dark blue precipitate, which was dried 
and collected as before. Elemental CHN analysis performed on the solid gave 
readings of 4.44 % C and 1.43 % H.
The precipitate obtained with the CO3 2- anion had a higher percentage of carbon 
compared with that obtained with sodium hydroxide, indicating the presence of 
carbonate as either a co-ordinated or/and unco-ordinated anion. FTIR spectra of 
the two precipitates were run (Figures 5.5 and 5.6) and both exhibited an intense 
C = 0  stretching band (1632 cm*i) and two lesser C = 0  stretches (1364 and 1319 
cm-i). A series of bands were also present at 822, 742, 603, 495 and 458 cm-i,
which correspond to Ti (UI)-0, C -0  and C-C stretching and chelate ring 
deformation.
Exposing the blue precipitates to air over a prolonged period, resulted in a loss of 
colour ascribed to the oxidation of the sample. On prolonged air exposure the 
complexes became brown in colour. FTIR spcctn performed on the oxidised white 
samples looked similar to those of the unoxidised blue Ti (III) precipitates (Figure 
5.7). The multinuclear Ti (III) species did however exhibit a broad band of 
medium intensity at 1511 cm * which was not present in the corresponding
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Figure 5.5 FTIR of Blue Titanium (III) Oxo/Hydroxo Complex Prepared with Titanium 
(IV) Potassium Oxalate and Sodium Carbonate.
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Figure 5.6 FTIR Spectrum of Blue Titanium (UI) Oxo/Hydroxo Complex Prepared 
with Titanium (IV) Potassium Oxalate and Sodium Hydroxide.
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Figure 5.7 FOR Spectrum of Oxidised (White) Titanium a«) Oxo/Hydroxo Complex 
Prepared with Titanium (IV) Potassium Oxalate and Sodium Hydroxide.
ISl
spectra of the oxidised solid. The brown solid, formed on further exposure to 
atmospheric oxygen, gave no significantly differing spectra.
c) Removal o f T1 (IV) Co-ordinated Oxalate with Calcium Chloride
5.0 mL of 0.20 mol dm-3 calcium chloride (C aC y  was added to 5.0 mL of 0.10 
mol dm-3 titanium (IV) potassium oxalate (K2TiO(C204)2). The white precipitate 
of calcium oxalate (CaC204) formed was filtered off and the clear supernatant was 
collected. To 5.0 mL of supernatant, 0.75g of zinc powder and 1.5 mL of 2.00 
mol dm-3 hydrochloric acid (HCl) solution was added. The reaction was left to 
proceed at ambient temperature for 30 minutes during which hydrogen gas 
evolved. The solution became pale yellow in colour. To 3.0 mL of the solution,
12.0 mL of 0.10 mol dm-3 sodium hydroxide was added, resulting in the 
precipitation of a pale grey-blue solid which rapidly decolourised on exposure to 
air to give a white solid thought to contain titanium (IV). The precipitate was 
washed, filtered and dried under vacuum in a desiccator. The white calcium 
oxalate precipitate only formed in the neutral solution. When attempting to reduce 
the titanium aV)-oxalate complex first, by adding the zinc and aqueous 
hydrochloric acid, the solution turned orange-brown as expected, but on addition
of the calcium chloride to this acidic medium, no calcium oxalate precipitate 
formed.
d) Additkm o f Citrate
1.0 mL of 0.50 mol dm-3 trisodium citrate solution was added to 1.0 mL of 0.20 
mol dm-3 titanium aV ) potassium oxalate and the mixture was left for 30 minutes. 
Then 2.0 mL o f 0.20 mol dm-3 „ f  calcium chloride was added to the solution and 
was allowed to stand for 15 minutes. The white precipiute of calcium
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formed was filtered off and 0.45g of zinc and 0.9 mL of 0.20 mol dm-3 
hydrochloric acid was added to 3.0 mL of the remaining supernatant. The reaction 
was allowed to proceed for 1 hour as hydrogen gas evolved. The solution changed 
colour from pale brown, through violet to deep purple, indicating complex 
formation and the transfer of Ti (III) from oxalate to citrate. To 3.0 mL of this 
solution, 18.0 mL of 0.10 mol dm'^ sodium hydroxide was added in order to 
precipitate a deep purple solid, which redissolved on addition of excess sodium 
hydroxide solution.
e) PiecipitatioD with Phosphate
1.5g of zinc powder and 3.0 mL of 2.00 mol dm*3 hydrochloric acid were added 
to 10.0 mL of 0.10 mol dm*3 titanium (IV) potassium oxalate (K2Ti*'^0 (C204)2) 
and allowed to stand for 30 minutes. Hydrogen gas evolved and the solution 
turned orange-brown in colour. To 3.0 mL of this solution was added 20.0 mL of 
phosphate buffer pH 7.41 which was prepared as described earlier. A violet-grey 
precipitate was formed, which faded in colour when allowed to remain in the 
supematent for 30 min. The white solid, thus obtained was filtered, washed in 
degased, distilled water and dried in vacuum.
S.2.2.2 Tissue Samples
During revision surgery of patients with aseptically loosened hip prostheses, 
acetabular tissue samples were taken. Metal debris was seen to be present in the 
tissues sampled. The prostheses had high density polyethylene acetabular 
components, backed with chrome-cobalt (Cr-Co) alloy. Ti-6A1-4V alloy screws 
were used to fix the acetabular component to the skeleton.
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The samples obtained were snap frozen by placing the fresh tissue in a sterilin 
cryotube, immersing the sealed tube into liquid nitrogen, and storing it at -70°C 
until needed for experimental work. Alternatively the tissue samples were fixed in 
10 % formol saline (2.5 dm^ formaldehyde (Infrachem), 212.5g NaCl (Sigma), 
diluted to 22.5 dm3 with distilled water) for 3 days. The tissue sample was then 
washed in a trihydroxymethylamine (BDH) buffered solution for 15 min, followed 
by washing in distilled water for 15 min to remove excess formol saline.
S.2.2.3 Synovial Fluid Samfries
Knee-joint synovial fluid samples from rheumatoid patients with knee 
inflammations were aspirated into plastic tubes (n =  5). After collection, the 
samples were sent to the laboratory packed in ice, where they were centrifuged at 
2,500 rpm for a duration of 15 minutes in order to remove the cells and debris. 
The resulting supernatant was stored at -TO^C for a maximum of 14 days.
S.2.2.4 FTTR Spectroscopic Analysis o f Prepared Titanium Ion Complex 
Precipitates and Titanium loo Containing Deposits from Failed Hip Implant Tissue 
Samples
FTIR spectra of the prepared titanium (III) and/or titanium (IV) complexes were 
run, as well as the spectrum of commercially available titanium (IV) dioxide 
(Ti02). A frozen tissue sample was defrosted at room temperature and the 
localised dark blue titanium containing deposit was manually extracted with 
tweezers and weighed. The sample was dried in vacuum in a desiccator. A
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normal, weighed tissue sample with no blue deposit was also dried and treated in 
the same way as the affected sample. KBr discs of the dried samples to be 
examined (ca. 2 % w/w relative to KBr) were prepared by grinding with a pestle 
and mortar. The spectra were recorded using a Digilab FTS 40 spectrometer. All 
the samples were scanned 16 times before the spectra were run and a resolution of 
8 was used.
S.2.2.S NMR Measuremeiits
0.07 mL of D2O was added to 0.60 mL of synovial fluid in a 5 mm diameter 
NMR tube, in order to provide a field-frequency lock. The Hahn spin-echo 
sequence (time delay, tp =  60 ms) was applied to the sample in order to supress 
the broad protein resonances and continuous secondary irradiation at the water 
frequency was applied to suppress the intense water signal. The Hahn spin-echo 
was carried out 128-212 times. The external reference for the synovial fluid 
spectra was sodium-3-(trimethylsilyl)-l-propane-sulphonate (TSP, 5=0).
Single pulse spectra of chemical model systems were also obtained. The pulse 
angle was 30-40® and the time delay between pulses was 3 seconds, in order to 
allow complete spin-lattice (Ti) relaxation of the protons within the sample. As 
before, the external reference was TSP.
In both cases the proton NMR measurements were carried out on a JEOL JNM- 
GSX spectrometer operating in quadrature detection mode at 500 MHz for ^H and 
at a probe temperature of 25®C.
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5.3 RESULTS AND DISCUSSIONS
The presence of blue-black discolorations in tissues adjacent to failed hip 
implants, discovered during revision surgery, has been reported previously. The 
discoloured tissue has been shown to contain titanium32. Although the 
discolouration can be due to naturally occuring titanium dioxide (Ti02) in the 
presence of impurities, the blue-black colour of the tissues sampled and that of the 
redox-dependent precipitates formed suggests that it occurs due to Ti (III) and/or a 
mixed Ti (III)/Ti (IV) complex. The localised deposit may consist of one or more 
complexes of titanium (III) bound to an anionic ligand that would be found in the 
human body, e.g. carbonate, phosphate or oxalate. A number of such ligands, 
including the hydroxide ion, were used to precipitate Ti (III) and/or Ti (III)/Ti 
(IV) complexes and the resultant precipitates colour was compared to that of the 
discoloured tissue sample.
A redox-active dark blue precipitate whose colour closely resembled that of the 
localised discolouration found on the failed hip implant tissue samples, was 
produced by reduction of titanium IV oxysulphate to titanium (III), with Zn/HCl, 
followed by subsequent precipitation with excess hydroxide or carbonate ions. The 
solid is probably an insoluble polynuclear titanium (III)-oxo and/or hydroxo 
complex or the hydrated mixed oxide of titanium (III) and titanium (IV), 
Ti305.nH20 . The titanium content of the precipitate was calculated to be 56% 
which is consistent with the polynuclear Ti (III) species with an approximate ratio 
of titanium:oxygen as 1 :2 .
Both the blue/black deposit isolated from the implant localised tissue samples and 
the synthesised dark blue precipitate discoloured on exposure to air {>12 hrs), 
becoming white in colour as oxidation to titanium (IV) occured, the hydrated 
titanium (IV) oxide, Ti0 2 .nH20  presumably being formed.
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The precipitate formed with carbonate was observed to oxidise more rapidly than 
the hydroxide-formed solid.
A phosphate buffer (pH 7.4) was used to precipitate a pale grey-blue Ti (III) 
solid. The titanium (III) was generated by the reduction of titanium (IV) 
oxysulphate (Ji^OSO^) with a Zn/HCl system. The solid contains one or more 
Ti (Ill)-phosphate complexes even though some of the Ti (III) oxo/hydroxo 
complexes were also probably present. The pH may also have affected the precipi­
tation and the formation of the complexes. The phosphate induced titanium (III) 
precipitate oxidised even more rapidly on exposure to air than the previously 
prepared complexes.
As the oxalate anion is a metal ion chelator and is therefore physiologically 
relevant, titanium potassium oxalate (K2TiO(C204)2) was used as the starting 
titanium (IV) salt. The precipitate was obtained as previously by reducing the Ti 
(IV) with a Zn/HCl system and then the dark-blue solid was dropped out of the 
solution by the addition of sodium hydroxide. The characteristic blue colour, 
similar to that obtained with titanium (IV) oxysulphate, indicates that the 
multinuclear titanium (III) oxo/hydroxo complex or the hydrated mixed titanium 
(III)/titanium (IV) oxide, TÌ305.nH20  was formed. The elemental CHN analysis 
gave the percentage of carbon as 4.44%, higher than expected suggesting the 
presence of Ti (III)- co-ordinated oxalate ion, as later confirmed by FTIR analysis 
of the dried sample.
A similar dark-blue precipitate was also formed with sodium carbonate as the 
precipitant. CHN elemental analysis of the solid derived in this way gave the 
carbon content as 6.12%; higher than that obtained with sodium hydroxide. This 
increased carbon content indicates the solid contains a significant quantity of co­
ordinated or non-co-ordinated carbonate ion.
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Both the precipitates obtained with OH- and CO3 2- became white in colour on 
prolonged (> 7 2  hrs) exposure to atmopheric oxygen.
The removal of the oxalate anion, in the K2Ti0 (C204)2 solution, prior to 
reduction of Ti (IV) to Ti (III), was carried out by calcium chloride. The white 
precipitate of calcium oxalate ( ^ ( € 204)2) was removed and the resulting 
supernatant, after reducion with the Zn/HCl system, yielded a blue-grey precipitate 
on addition of NaOH. This product was unstable in air, as it quickly auto-
oxidised. Colour of solid was unaffected by the continuous purging with nitrogen 
gas throughout the reaction.
The action of the endogenous chelator citrate on the colour and solubility of 
titanium (III) was also studied. A solution with the (Ti0 (C204)2]2- anion was 
sequentially treated with a) 2.50 molar equivalents of trisodium citrate and b) 2.00 
molar equivalents of calcium chloride (C aC y  to remove the oxalate in the form 
of insoluble calcium oxalate. The reduction of the supernatant with Zn/HCl 
yielded a deep purple solution, which on addition of sodium hydroxide, gave a 
purple precipitate, presumably a complex of one or more titanium (Ill)-citrate
complexes. The precipiute redissolved on the addition of excess NaOH. and the 
solution became clear.
Treating the Zn/HCl reduced titanium oxalate solution with phosphate buffer, (pH
7.41) yielded a violet-grey precipitate, o f probably one or more titanium (III)-
phosphate complexes. The precipiute rapidly oxidised to white, on exposure to 
air.
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Titanium (III) is a powerful reducing agent (the redox potential, of the 
Ti*V(OH)2 2+/Ti 3+ system is estimated to be 7.7 xlO-3 V) and therefore the 
oxidation of the newly formed Ti (III) (or mixed Ti (III)/Ti (IV)) complexes are 
to be expected. The violet Ti (III) ions readily donate electrons to molecular 
oxygen. The hexaaquatitanium (III) complex ([Ti(H20 )6]3'^) does not directly 
interact with molecular oxygen, even though O2 does oxidise the hydroxotitanium 
(III) ion ([Ti(H20 )5(OH)]2+) to Ti (IV) (Ti02 ‘‘■) by an outer-sphere pathway 
which generates the superoxide anion (CP*)>
The reaction is slow at room temperature (second-order rate constant, k2 =  4.25 
mol dm-3 s-i). The oxidation of the insoluble titanium (III) complex present as 
localised titanium deposits in tissue adjacent to failed Ti-6A1-4V alloy prostheses, 
may play a significant part in promoting the generation of reactive oxygen radicals 
in vivo. However, these reactions are expected to be retarded in the envir^ment of 
the inflammed rheumatoid joint which has a diminished amount of oxygen in the 
tissues, i.e in a hypoxic enviroment.
On further exposure of the white titanium dioxide (Ti0 2-nH20 ) solid (derived 
from the oxidation of the deep blue mixed Ti (III)/Ti (IV) oxide) to the 
atmosphere a yellow/brown discolouration was observed. This colour change was 
thought to be due to the presence of the white/yellow titanium (IV) hydroxide 
species in the product.
5.3.1 FTIR Spectroscopic Analysis
The titanium (III) compounds prepared (including the polynuclear titanium (IV) 
oxo/hydroxo complexes and their autoxidation products) were examined by FTIR 
spectroscopy to help elucidate their structure. The absorption bands displayed, as 
mentioned earlier, were attributable to Ti (III)-O stretches and to the multinuclear
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species derived from titanium (IV) oxysulphate (Tid'^)0 S04) or titanium (IV) 
potassium oxalate (K2Ti^^>0 (C204)) which contained titanium (III) co-ordinated to 
the respective sulphate or oxalate. The presence of oxalate was further implied by 
a carbon content of ca. 5%, as given by elemental CHN analysis.
The localised dark blue/black prothesis-derived tissue samples were manually 
isolated from affected tissues obtained from patients undergoing revision surgery 
and were examined by FTIR spectroscopy. A typical FTIR spectrum of such a 
sample is shown in Figure 5.8. A very broad absorption band is seen in the 
lower region at 800-400 cm*^ which could be due to the presence of Ti (III)-O 
and/or Ti (IV)-O stretches. A FTIR spectrum of commercially available titanium 
(IV) oxide (Ti02) was run and as seen in Figure 5.9, exhibited two intense bands 
at 672 and 532 cm*i. This suggests that the Ti-O stretches present in the spectrum 
of the tissue sample could be attributed to Ti (IV)-O stretches of the Ti0 2nH20 
formed on the oxidation of the blue coloured titanium oxo/hydroxo complex, 
together with underlying Ti (III)-O stretching bands of the complex itself. The 
complex tissue sample spectrum also exhibits numerous other absorption bands, 
which can be tentatively assigned to endogenous protein, polysaccharide and other 
low molecular weight components.
The stretches at 1652 and 1636 cm-^, are attributed to amide and C = 0  stretches 
arising from proteins. The regions of 1610-1550 cm*» and 1420-1300 cm-i indicate 
the respective antisymmetrical and symmetrical stretches of the carboxylate anion. 
The presence of overlapping bands in the 1150-1000 cm-^ region may point 
towards the presence of some titanium (III) or titanium (IV) co-ordinated 
phosphate. A typical spectrum of a synovial tissue sample derived from a patient 
with no joint prothesis is shown in Figure 5.10 as a reference.
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Figure 5.8 FTIR of a Localised Blue/Black Tissue Sample From a Patient Undergoing 
Revision Surgery for a Failed Titanium Alloy Hip Implant.
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Figure 5.9 FTIR of Titanium Dioxide.
162
a- hO S  
uJ • 
E ZD OO D to il 
c: to  to  
a< • u J > i— 01
(S
o
Figure 5.10 FTIR of Tissue Sample from a Patient with No Titanium Alloy Hip 
Implant.
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S.3.2 High F idd  ProCoo Hahn Spin-echo NMR Analysis o f Synovial Fluid Treated 
with Titanium (IV)
Hahn spin-echo was used to ascertain the molecular nature and spéciation of the 
titanium (IV) ions in the synovial fluid surrounding the implant joint. Successive 
increasing concentrations of [Ti*''0 (C204)2]2- (0.10-1.52 x 10-3 mol dm-3) solution 
were introduced to the synovial fluid samples (Figs. 5.11 and 5.12). A small 
amount of a white solid was seen to be precipitated. There was a notable 
broadening of the peaks attributable to the citrate -CH2-. The peaks attributable to 
the succinate -CH2- and the acetate -CH3 were seen to a lesser extent, as the time 
delay between the pulses was adjusted so as to be close to their spin-spin 
relaxation times. This indicates that these endogenous oxygen-donor ligands 
interact with the [Ti0 (C204)2]2’ to give rise to titanium (IV)-citrate and/or ternary 
titanium (IV)-citrate-succinate or titanium (IV)-citrate-acetate complexes by way of 
ligand substitution involving the release of one or both of the oxalate ligands from 
the titanium (IV) complexation sphere.
The initial formation of the transient white precipitate on addition of the titanium 
(IV) oxalate salt is consistent with the observed formation of insoluble calcium 
(Il)-oxalate derived from the relatively high concentration (ca. 2 x 10*3 mol dm-3) 
of Ca^“^ ions found within synovial fluid.
Subsequent addition of excess ascorbate (1.00 x lO-  ^ mol dm-3) (q the titanium 
(TV)-synovial fluid samples and equilibration for 45 minutes at ambient 
temperature produced a "sharpening” of the peaks attributable to citrate (Figure 
5.13). This sharpening demonstrated the transfer of Ti (IV) from citrate to 
ascorbate. In this instance, ascorbate probably takes on the role of a bidentate 
oxygen donor ligand.
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It has long been known that titanium forms an intensley orange complex with 
ascorbate^^* in aqueous solution. This orange colour was seen on the addition of 
excess ascorbate to the titanium-containing synovial fluid sample, indicating the 
formation of one or more titanium (IV)-ascorbate or ternary titanium (IV)- 
ascorbate-citrate complexes. The colour change occurs due to an oxygen-to- 
titanium (IV) (ligand to metal ion) charge transfer absorption band centered in the 
near UV region of the electromagnetic spectrum at ca. 360 nm.
It has been postulated that the predominant titanium species in excess ascorbate 
is a tris-(ascorbato) Ti (IV) complex ([Ti(Asc)3]2-), which is formed in aqueous 
solution at pH 4. The proposed octahederal complex is thought to have three 5- 
membered chelating rings, involving the neighbouring deprotonated hydroxyl 
oxygen atoms which act as donor atoms, and are found on the unsaturated 
heterocyclic ring of the ligand. The chelate is discouraged from undergoing an 
intramolecular redox reaction due to the stability of titanium (IV) relative to 
titanium (III), that is to say that the redox potential of the Ti (III)/Ti (IV) system 
is low.
In all the 5 synovial fluid samples studied, the ascorbate dependant resharpening 
of the titanium broadened citrate resonances were reproducible. However, in every 
case the resharpening of the citrate resonances did not reach completion, even on 
prolonged exposure (> 2 4  hr) the peaks did not return to the state prior to 
treatment with titanium (IV). This indicates that ascorbate has a lower affinity for 
Ti (IV) than citrate.
168
5.4 CONCLUSION
The coloured titanium (III) oxo/hydroxo complexes were produced relatively 
easily from the implant derived Ti (III) ions and this is not surprising considering 
the hydrolysis of the hexaaqua cation ([Ti(H20)6]3+) is thermodynamically 
favoured. Pecsok and Fletcher^io reported the rapid formation of such a 
polynuclear titanium (III)-oxo/hydroxo species at pH values above 3.5, which were 
more sensitive to oxidation than either Ti3+ or TiOH2+. They also showed that 
electronic absorption spectra of aqueous solutions of these species gave a number 
of diffuse bands which spanned the entire visible region of the spectra. The bands 
were responsible for the stability of the black colour of the solutions upon the 
addition of the chelator sodium tartrate.
As with the polynuclear titanium (III) species synthesised, iron (III) chelate 
complexes also readily polymerise to form the multinuclear iron (III)-oxo/hydroxo 
species. The two metals have in common similar hydrolytic equilibria as 
illustrated:
[Ti(H20)eJ3+ +  OH- [Ti(H20)5(0H)-]2-^ +  H2O log^o Ki = 11.8
[Fe(H20)6]3+ +  O H ^ = ±  [Fe(H20)5(0H)-]2+ +  H2O log^o K, = 11.6
The polynuclear titanium (III) complex derived from the titanium alloy prosthesis, 
manifests itself as a localised, insoluble deposit in the interface tissue, since the 
physiological pH readily facilitates precipitation of such a species. However in the 
inflammed joint enviroment, it is possible that chelators such as phosphate, 
sulphate, citrate or oxalate (oxalate is present only in very low levels in normal 
biological fluids; /xmol.dm-^ or below in normal human plasma) are capable of 
retaining some of the titanium (UI)-oxo/hydroxo polymers in solution.
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The relatively rapid oxidation of the synthetically produced Ti (III)-oxo/hydroxo 
complexes, upon exposure to air is significant in view of its potential ability to 
generate the superoxide anion by electron transfer to molecular oxygen in vivo:-
[..TiflU)OTi(*n) (OH)..]3+ +  O2 ------- > [ ..Ti(*v)OTi(H*) (OH)..]^+ + O 2 -
Reactions such as these, are however retarded in an anoxic enviroment and as the 
titanium is detected as Ti (III) rather than Ti (IV) when newly isolated from the 
tissue sample, this indicates that a reduction, such as expressed, occurs to a 
limited extent, if at all. Indeed, the abnormal profile o f a chronically inflammed 
joint is partly characterised by the hypoxic (diminished oxygen) enviroment of the 
joint, and as such would retard the radical generating pathways. The titanium may 
be partly stabilsed by the reducing enviroment of the biological matrices due to the 
presence of electron donors such as thiols in the form of cysteine or glutathione.
Polynuclear titanium (III)-oxo/hydroxo complexes may promote the destructive 
generation of »OH radicals from peroxide (H2O2) even though the relative 
insolubility of such a titanium (III) species at a physiologically relevant pH, will 
likely modulate the extent of these reactions in vivo.
Tengvall et suggested that as well as the production of the oxidising
Ti(IV)02 ■ (OH*)y species from the reactions of titanium (IV) with protonated 
superoxide (HO2), or Ti(IV)02 (OH*),  ^ with the .OH radical, the oxidant may 
also form due to the direct interaction of titanium (III) from the implant with 
molecular oxygen. This reaction pathway could also be brought about due to an
increase in oxygen pressure, derived from titanium metal mediated hydrogen 
peroxide decomposition.
170
The relatively rapid autoxidation of the titanium (III)-oxo/hydroxo complex 
reported in this work supports the hypothesis that the superoxotitanium (IV) 
component is derived fron Ti (III).
Also possibly present in the affected tissue, is the dark blue coloured mixed 
titanium (III)/titanium (IV) oxide (TijOj) and it may significantly contribute to the 
distinctive blue/black colour observed. It has been reported that the thermal 
oxidation of titanium metal gives rise to a layered structure consisting of TiO, 
Ti203, Ti305 and Ti02 in the given order, from the oxide interface to the surface. 
The lower titanium oxides are formed first and their potentially continous 
oxidation and regeneration is likely to have important biological consequences for 
the bone-implant interface of the titanium prosthesis. The hypoxic enviroment of 
the inflammed rheumatic joint may promote the lifetime of such species in vivo.
Treating rheumatoid synovial fluid samples with increasing concentrations of 
titanium (IV) and following the reactions using Hahn spin-echo NMR 
spectroscopy, provided evidence that citrate, acting as a tetradentate oxygen donor 
ligand complexes with non-protein bound titanium. A significant amount of the 
titanium (IV) is probably derived from the autoxidation of polynuclear Ti (III)- 
oxo-hydroxo species in vivo. There was an observable broadening of citrate 
resonances on addition of 0.10-1.03 x 10*3 mol dm*3 Ti (IV) to the synovial fluid 
samples. The resonances due to succinate and acetate were broadened to a lesser 
extent. The NMR spectra suggest that the non-protein bound, low-molecular mass 
titanium (IV) is mainly present as titanium (IV)-citrate complexes. The relatively 
low level of broadening observed in the succinate and acetate resonances, is 
probably due to their involvment with titanium (IV) and citrate in the formation 
of ternary Ti (IV)-citrate-succinate and Ti (IV)-citrate-acetate complexes. Even 
though the amount of citrate present in rheumatoid synovial fluid will significantly
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vary between patients (ca. 0.5-4.5 x 10^ mol dm*^), it is expected to be present in 
excess compared to the level of implant derived Ti(IV) in vivo^  so facilitating the 
formation of titanium (IV)-complexes.
Considering the prevalence of Ti(IV)-0 in titanium (IV) chemistry it is not 
suprising that the endogenous citrate molecules complex with titanium (IV). 
Recently work has been carried out using proton NMR spectroscopy, showing the 
ability of citrate to complex with low-molecular mass (non-transferrin bound) iron 
(III) in rheumatoid synovial fluid^^^.
Incubating the titanium (IV) loaded synovial fluid with excess ascorbate produced 
changes in the citrate resonances. This demonstrates that the titanium (IV) is 
partially transferred from the citrate to the ascorbate ligand under the experimental 
conditions. The concentrations of the (reduced) ascorbate within the rheumatoid 
synovial fluid are, however, depleted due to the fact that ascorbic acid is prone to 
oxidative damage by way of highly reactive oxygen radicals (e.g OH radicals). 
Indeed, the concentration of ascorbate in synovial fluid (ca. 8.0 x 10^ mol dm-3) 
has been shown to be notably lower than that of dehydroascorbate (ca. 3.3  x lO-^  
mol dm-3). Therefore the concentrations of ascorbate in rheumatoid synovial fluid 
are of a level which would greatly limit its ability to compete with other 
endogenous chelating ligands such as citrate.
In conclusion, this work has gone some way in identifying the chemical nature of 
titanium metal as found in the previously observed and reported phenomenon, of 
staining of the tissue adjacent to failed hip prosthesis implants. FTIR and NMR 
has been used to provide an overview of the prosthesis derived titanium (III) and 
titanium (IV) species. The proliferation of these species may be harmful and by an 
understanding of their chemical nature, theur^)eutic agents may be investigated 
which may chelate with the redox active metal ions.
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CHAPTER 6
SPECIATION OF NON-TRANSFERRIN BOUND IRON IN 
SYNOVIAL FLUID OF RHEUMATOID ARTHRITIS PATIENTS 
BY PROTON HAHN SPIN-ECHO NMR.
173
6.1 INTRODUCTION
It has been reportedisi that the knee joint synovial fluid o f rheumatoid arthritis 
patients contains non-transferrin bound iron. The iron is redox-active and can 
readily act as a catalyst to promote the production of the hydroxyl radical ( OH) 
from the superoxide radical ion (O^ ■) and hydrogen peroxide (H3O3) which are 
released from inflammed sites by activated polymorphnuclear leucocytes and
macrophagesi^2^
The one-electron reduction of oxygen (Oj) produces the superoxide radical ion, 
O2 Superoxide is formed in almost all aerobic cells, a major source being the 
"leakage" of electrons on to O , from various components of the cellular electron 
transport chains. An elevated oxygen concentration increases the Oj ■ production 
by activated phagocytic cells. TTie superoxide radical undergoes a dismutation 
reaction, which at physiological pH occurs in two stages:
O2 +  H+ ^H O o (6. 1)
HO2 +  O ,-  +  H+ H2O2 +  Oo (6 . 2)
Hydrogen peroxide. is produced from the superoxide radical ion by a non-
enzymic or an enzymic superoxide dismutase (SOD) catalysed dismutation
reaction. The and are relatively poorly reactive in themselves, in aqueous
solution, but the iron dependent decomposition o f hydrogen peroxide generates the
highly reactive hydroxyl radical, -OH. The soKialled Fenton reaction (Equation
6.3) follows the production of the hydroxyl radical from the which occurs 
only in the presence of iron.
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Fe2+ + HoO2^2 ^  OH +  Fe3+ +  OH- (6.3)
Traces of Fe^ -*- can react further with H2O2:
Fe3 + + H2O2 -^ ‘ Fe^ -»- + 2H+ +  O2 - (6.4)
Overall the reaction taking place can be summarised in the metal-catalysed Haber- 
Weiss reaction (6.5).
O2 ■ +  H2O2 ^ 0 2 +  OH +  OH- (6.5)
The hydroxyl radical readily reacts with molecules at or close to its site of 
formation, modifying the existing biomolecules with deleterious effect. These 
degradation products can stimulate synovitis and can be responsible for progressive 
joint destructioni53.i54, por this reason it is important to investigate the chemical 
nature of the non-transferrin-bound iron.
For many years it as been known that there are abnormalities in the iron 
metabolism of rheumatoid arthritis patients^^s.ise. There is a rapid fall in the total 
iron content of blood plasma at the onset of inflammation. This is followed by a 
drop in haemoglobin concentration and an increased deposition of iron proteins in 
the synovial membrane and fluidi57. The iron in the synovial fluid is largely 
present within ferritin. Halliwell et reported the presence of ’’free" iron
within RA synovial fluid by development of a specific test that detects non-protein 
bound iron in biological fluids. This test makes use of bleomycin, an anti-tumour 
antibiotic which degrades DNA. The degradation by bleomycin is absolutely 
dependant on the presence of Fe2+ ions and so the rate of degradation can be used 
to asses the "free" iron content of the system. They reported that the small but
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significant amount of non-transferrin bound iron, is enough to allow the formation
of the OH from O2 ’ and H2O2 generated by the phagocytes in the rheumatoid 
joint.
Halliwelly Gutteridge and Blake^^’ postulated that the formation of hydroxyl 
radicals is at least parüy responsible for cartilage damage. They hypothesised that 
the presence of the "free" iron was due to a creation of a microenviroment by the 
"sliding over" of phagocytes over cell surfaces, the pH of which can fall to 5 or 
below. This acidic enviroment would facilitate the release of iron from transferrin 
and would account for the presence of the non-protein bound iron.
As the role of iron in free radical generation is very important, it would be 
beneficial to investigate the spéciation of the "free" iron in the biological system. 
It has been reported that the chromatographic fractionation of biological fluids 
leads to protein degradation and to metal ion releasei«>. The development of an 
alternative analytical method would therefore be appropriate. Ideally this method 
would involve little or no pre-treatment. To this purpose nuclear magnetic 
resonance (NMR) spectroscopy was investigated as a possible alternative method 
for the metal spéciation of the low-molecular weight iron. This technique has been 
successfully utUised for the study of biological fluids and has been found to be 
useful in providing details on the concentration and mobility o f many low- 
molecular mass metabolites in biological fluidsi^i. By using Hahn spin-echo NMR 
and desferrioxamine, a strong hexadentate iron (III) chelator, the low molecular 
weight, non-transferrin bound iron present in the synovial fluid of rheumatoid 
patients can be speciated as described in the following work.
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6.2 MATERIALS AND METHODS
6.2.1 Materials
Desferrioxamine (Desferal, desferrioxamine B methanesulphonate) was provided 
by Ciba-Gcigy, and analytical grade iron (III) chloride was obtained from BDH 
Pharmaceuticals.
Proton NMR spectra were obtained on a JEOL GSX-5(X) NMR spectrometer 
operating at 500 MHz.
6.2.2 Methods
Knee joint synovial fluid from rheumatoid arthritis patients was drawn into 
heparinised tubes (n=9). Heparin is a drug used for its anti-coagulant properties. 
It is a polysaccharide composed of D-glucosamine and D-glucuronic acid units, 
with N- and O- sulphate esters. It is obtained from beef liver, lung or small 
intestine.
The samples were centrifuged at 400g for 15 minutes and were then either used 
for analysis within a few hours of collection, or were stored at -70°C until 
needed. Serum samples were prepared by letting the freshly obtained blood, from 
non-heparinised tubes, clot. These serum samples were stored at -70®C also. 
Control experiments earned out at the Royal London Medical School showed that
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none of the criteria studied changed significantly during storage. The preparation 
of the biological samples prior to their analytical investigation, was carried out by 
the staff at the Bone and Joint Unit, at The Royal London Medical School.
6.2.3 NMR Measuiements
A portion of knee joint synovial fluid (0.60 mL) was introduced to a 5 mm 
diameter NMR tube and to it was added 0.20 mL of deuterium oxide (D2O) to 
provide a frequency lock. A Hahn spin-echo pulse sequence, D[90 x- T -180 y- T 
-collectjn was performed, where n =  342-354. The value of T =  60 ms; this 
being the time after which all the resonances due to the high molecular weight 
proteins have relaxed and are therefore removed from the spectrum. As explained 
in Chapter 2, this pulse sequence "cleans up" the spectra by the removal of broad 
signals due to proteins. A gated secondary irradiation was applied at the water 
frequency to remove the intense water signal from the spectrum. The samples 
were run using sodium-3-(trimethylsilyl)-l-propane-sulphonate (TSP), ^  =  0 ppm) 
as an external reference.
On completion of this measurement, 0.02 mL of the iron chelating drug 
desferrioxamine (3.00 x 10^ mol dm-3) was added to the NMR tube which was 
left for over 6 hours, to allow equilibration to take place. After this time another 
NMR spectrum was run using the same protocol.
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6.3 RESULTS AND DISCUSSION
Figure 6.1 shows the proton Hahn spin-echo NMR spectrum of a typical synovial 
fluid sample from a patient with rheumatoid arthritis. Figure 6.2 shows the 
difference in the intensity of the peaks attributable to citrate before and after 
addition and incubation with desferrioxamine. It can be seen that there is a small 
but reproducible increase in the characteristic citrate resonances when 
desferrioxamine is present. This result would suggest that some of the low 
molecular weight non-transferrin bound iron present in the synovial fluid is bound 
to the citrate. To reaffirm this observation, iron (III) chloride (l.(X) x 10^ mol 
dm-3) was added to the sample which was then incubated for 2 hours. A localised 
NMR spectrum was run. From figure 6.3 it can be seen that the addition of the 
iron (III) led to a marked broadening of the characteristic AB coupling pattern of 
the citrate resonances. The addition of a higher concentration of iron (III) chloride 
(2.00 X 10^ mol dm-3) to the synovial sample led to the disappearance of the 
citrate resonances from the spectrum altogether. Similar results were obtained from 
five different samples studied.
The resonances of other potential chelators of the iron (III), such as acetate and 
glutamine, were virtually unchanged by the addition of the iron (III) chloride, 
even at the higher concentration. This would seem to indicate that citrate is a 
highly selective chelating ligand of non-transferrin bound iron in synovial fluid.
The iron (III)-loaded samples were subsequently treated and incubated (6h) with 
an excess of desfemoxamine (2.5 x 10^ mol dm*^). A spectrum obtained showed 
that the citrate resonances reappeared, demonstrating the transfer o f the low 
molecular weight iron from the citrate ligand to the iron chelating drug 
desferrioxamine.
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(C)
(b )
(a)
R guie 6.3 500 MHz Proton Spin-echo NMR Spectra of a Typical Sample of 
Rheumatoid Synovial fluid (a) Untreated Sample (b) With the Addition of 1.00 x l(H 
mol dm-3 Iron (ni) and (c) With the Addition of 2.00 x 1 (H  mol dm-3 Iron aH).
The Iron Added was in the Form of TICI3.
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The changes in the citrate resonances, within a synovial fluid sample incubated 
with desferrioxamine, demonstrate the ability of citrate to chelate these low levels 
of non-transferrin bound iron (ca. 1-8 x 10^  mol dm-3)i56. This function is very 
important since the iron can act as a potential catalyst within the biological fluid. 
As already mentioned, Halliwell and Gutteridgei59 explained the presence of low 
molecular weight iron in rheumatoid synovial fluid by the drop in pH of the 
enviroment, which facilitates the release of iron from transferrin. Further 
studies!« proposed that the iron could be liberated from ferritin by chelators such 
as citrate and acetate. High resolution proton NMR and HLPC work by Grootveld 
et 0/!«  indicated that the low molecular weight iron (III) is present as an iron- 
citrate and/or ternary iron-citrate-acetate complex. In this study however there 
was no indication that the acetate ligand was acting as a chelator of the non­
transferrin bound iron (III).
The levels o f non-protein bound citrate, that are detected by NMR in synovial
fluid samples, can vary widely both between, and within patients (ca. 0.5-4.5 x
1(H mol dm-3). Citrate is always present in excess compared to the non-transferrin
bound iron. At a neutral pH, the main iron aH)-citiate complex formed is likely
to be iron (III)-monocitrate, with all the three carboxylate groups and the hydroxyl
group deprotonated. At a more acidic pH, the 1:2 [Fe(citrate)2]3- complex forms,
and is present as 40 mol % fraction of the total iron concentration at pH 5 in an
isolated iron (in)-citrate systemi64. u  seems probable that the iron-citrate
complexes form a major component of the catalytic, low molecular weight iron in 
synovial fluid.
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6.4 CONCLUSION
It can be seen that proton Hahn spin-scho NMR sectroscopy provides us with an 
invaluable analytical tool with which to study the spéciation of the metal ions such 
as iron (III) within synovial fluid from rheumatoid arthritis patients. With a 
minimum of sample treatment, metal ion abnormalities of inflammatory joints have 
been followed. It can be concluded that the low molecular weight iron present in 
the rheumatoid joint, which is deleterious to its surroundings because of its ability 
to readily promote production of free radicals, is present as a low molecular mass 
iron (Ill)-citrate complex. The harmful presence of the "free" iron can be 
controlled by the application of the drug desferrioxamine (Desferal), which as 
shown in this work effectively chelates the potentially catalytic iron.
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CONCLUSIONS
Bone and joint disease is the most common ailment amongst the elderly 
population. Much research has been done to investigate the causes and mode of 
action of effective drugs to control the disease, especially in the field of 
rheumatoid arthritis. As this study shows, metal ions, particularly low molecular 
weight ions, play an important role in bone and joint disease, whether they are 
present naturally within the biological environment, or are introduced, as is the 
case with gold containing drugs and titanium alloy implants. The spéciation of the 
relevant free metal ions will go a long way in helping us to elucidate what is 
happening in the diseased tissues.
Chrysotherapy with gold containing drugs such as disodium aurothiomalate, have 
been known to induce remission in rheumatoid arthritis sufferers. Most of the gold 
is protein bound in the body, but 5-10% of the gold is present as low molecular 
weight gold. This gold is of interest as it would seem to play an important role in 
the attainment of chemical equilibrium and in transport processes.
Initial work with the formation of a spectroscopically active Au-dithizonate 
complex was abandoned after the realisation of the instability of the complex and 
therefore its unsuitability for the development of a working low molecular gold 
analysis method.
Using HPLC and atomic absorption spectroscopy as a corroborative tool, a 
viable qualitative and quantitive analytical method was set up which was used to 
measure the levels of low molecular weight gold in plasma and synovial fluid 
obtained from rheumatoid arthritis patients undergoing a course of chrysotherapy. 
The synovial fluid was found to have in the region of 2.0 x 1(H mol dm-3 of
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low molecular weight gold and plasma samples about 4.0 x IQ-  ^ mol dm*3 of the 
non-protein bound gold. This study derived a relatively speedy method for the 
detection of non-protein bound gold by complexing the gold with cyanide and 
detecting the resultant dicyanoaurate complex. The method provided an analysis 
which was sensitive enough for detection of gold at the biologically relevant levels 
with very little need for pre-treatment. Further work should be done on an 
effective and quick method for the analysis of protein bound gold.
Titanium implants used in hip replacements, have been employed for many years 
because of their inert properties. However in failed hip replacement operations, 
dark staining in tissue adjacent to the prostheses has been noticed in some cases. 
FTIR was used in this study to show that the dark stained tissue contained Ti 
complexes, thought to be a mixture of Ti(III)/Ti(IV) complexes. Furthermore 
Ti(III) complexes were synthesised in vitro which displayed the dark blue colour 
as seen in the tissue samples. NMR studies carried out gave evidence that non­
protein bound Ti(IV) is mainly present in the form of a Ti(lV)-citrate complex. 
The work carried out, helped to identify the chemical nature of the Ti metal found 
in the stained tissue. These metal ions may be harmful and further work would 
need to be earned out to find a suitable chelator to act as a therapeutic agent.
The abnormalities in the iron metabolism of RA patients has been known for 
many years. The presence of non-protein bound iron in RA synovial fluid has 
been documented. As the presence of the 'free' iron encourages free radical 
generation which is deleterious to the biological system it is important to speciate 
the metal ion. NMR provided an analytical tool with which to study the spéciation 
o f Fe with the minimum of sample pre-treatment. It was seen that the free iron 
was present in synovial fluid as a low molecular mass Fe(III)-citrate complex. 
Application of the drug desferrioxamine, successfully chelated the free iron. 
Further work would include the quantifying of the free iron.
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The 'free' low molecular weight, or non-protein bound metal ions, present in 
bone and joint diseased tissues and fluids are of importance because of their more 
reactive nature and greater 'mobility' compared to protein-bound metal moieties. It 
is therefore very probable that they play a pivotal role in any therapeutic or 
deleterious effects due to the presence of metal ions within bone and joint diseased 
systems, and as such their study is of interest.
In this study a wide range of analytical methods were employed, including 
HPLC, A A spectroscopy FTIR and NMR. These analytical tools allowed the study 
of a differing range of 'free' metal ions encountered in bone and joint disease, and 
so in some way increased the understanding of the metals role and action within 
the biological system of the diseased tissue.
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